(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 8 May 2003 (08.05.2003)

PCT

(10) International Publication Number WO 03/037274 A2

(51) International Patent Classification7:

A61K

(74) Agents: MANN, Jeffry, S. et al.; Townsend Townsend

(21) International Application Number:

PCT/US02/35172

(22) International Filing Date:

1 November 2002 (01.11.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/335,958

1 November 2001 (01.11.2001)

(71) Applicant (for all designated States except US): ICA-GEN, INC. [US/US]; Suite 460, 4222 Emperor Boulevard, Durham, NC 27703 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ATKINSON, Robert, Nelson [US/US]; 11908 Radner Way, Raleigh, NC 27613 (US). GROSS, Michael, Francis [US/US]: 6200 Chesden Drive, Durham, NC 27713 (US).

and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: PYRAZOLE-AMIDES AND-SULFONAMIDES

	A	
compound #	Structure	MZ
790	ation	405
791	\$#\$c	Gr.
6 331	10 pto	482
1043	8040	516
1047	~~~.	439
1048	routo.	457
1124	32:50	524
1125	rais	461

	, В	
1126	ray.	447
1128	40	475
1129	S. T. C.	487
1149	321400	459
1150	*oito.	487

(57) Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazole-amides and -sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.

WO 03/037274 A2



Published:

upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidwithout international search report and to be republished ance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PYRAZOLE-AMIDES AND -SULFONAMIDES

CROSS-REFERENCES TO RELATED APPLICATIONS

This is a non-provisional filing of United States Provisional Patent

Application Number 60/335,958, filed on November 1, 2001, the disclosure of which is

incorporated herein by reference in its entirety for all purposes.

FIELD OF THE INVENTION

This invention relates to the use of certain pyrazole amide and pyrazole sulfonamide compounds as sodium channel inhibitors and to the treatment of neuropathic pain by the inhibition of sodium channels. Additionally, this invention relates to novel pyrazole-based compounds that are useful as sodium channel inhibitors.

10

15

20

25

30

BACKGROUND OF THE INVENTION

Sodium channel-blocking agents have been reported to be effective in the treatment of various disease states, and have found particular use as local anesthetics and in the treatment of cardiac arrhythmias. It has also been reported that sodium channel-blocking agents may also be useful in the treatment of pain, including neuropathic pain; see, for example, Tanelian et al. Pain Forum. 4(2), 75-80 (1995). Preclinical evidence demonstrates that sodium channel-blocking agents selectively suppress abnormal ectopic neural firing in injured peripheral and central neurons, and it is via this mechanism that they are believed to be useful for relieving pain. Consistent with this hypothesis, it has been shown that sodium channels accumulate in the peripheral nerve at sites of axonal injury (Devor et al. J. Neurosci. 132: 1976 (1993)). Alterations in either the level of expression or distribution of sodium channels within an injured nerve, therefore, have a major influence on the pathophysiology of pain associated with this type of trauma.

An increasing body of evidence suggests that a voltage-dependent, tetrodotoxin (TTX)-resistant Na channel, PN3 (Na_v1.8), may play a key role in sensitization in neuropathic pain states. Neuropathic pain can be described as pain associated with damage or permanent alteration of the peripheral or central nervous system. Clinical manifestations of neuropathic pain include a sensation of burning or electric shock, feelings of bodily distortion, allodynia and hyperalgesia.

PN3 is a member of a family of voltage-gated sodium channel alpha subunits. Names for this family include SCN, SCNA, and Na_vx.x. There are currently 10

known members falling into two subfamilies Na_v1 (all but SCN6A) and Na_v2 (SCN6A). The human channel was cloned by Rabert *et al.* (*Pain* 78(2): 107-114 (1998)). PN3 of other species has also been cloned. *See*, for example, Chen *et al.*, *Gene* 202(1-2), 7-14 (1997); Souslova *et al.*, Genomics 41(2), 201-209 (1997); Akopian *et al.*, *Nature* 379(6562), 257-262 (1996).

5

10

15

20

25

30

PN3-null mutant mice exhibit a pronounced analgesia to mechanical noxious stimuli (Akopian A.N. et al., Nature Neurosci., 2(6): 541-548 (1999)). Selective "knock down" of PN3 protein in the rat dorsal root ganglion with specific antisense oligodeoxynucleotides prevents hyperalgesia and allodynia caused by either chronic nerve or tissue injury (Porreca et al., Proc. Nat. Acad. Sci., USA, 96: 7640-7644 (1999)). The biophysical properties of PN3 make it ideally suited to sustain repetitive firing of sensory neurons at the depolarized potentials characteristic of injured peripheral nerves. In both human and animal models of neuropathic pain, there is an increased expression of PN3 at the site of peripheral nerve injury (Clare et al., DDT 5: 506-519 (2000); Coward et al., Pain 85: 41-50 (2000)).

Patients with neuropathic pain do not respond to non-steroidal anti-inflammatory drugs (NSAIDS) and resistance or insensitivity to opiates is common. Most other treatments have limited efficacy or undesirable side effects. Mannion *et al.*, *Lancet*, 353: 1959-1964 (1999) from the Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School wrote: "There is no treatment to prevent the development of neuropathic pain, nor to adequately, predictably and specifically control established neuropathic pain."

PN3 is a promising molecular target for the treatment of neuropathic pain. One of the most attractive features of PN3 is the highly restricted and peripheral nature of its expression. Antisense studies have revealed no overt (particularly CNS-related) adverse effects, consistent with the localized, peripheral distribution of the channel (Novakovic et al., J. Neurosci., 18(6): 2174-2187 (1998)). Additionally, the high activation threshold of PN3 suggests that the channel may be relatively uninvolved in normal nociception. These properties of PN3 present the possibility that selective blockade of this particular voltage-gated sodium channel (VGSC) may offer effective pain relief without the significant side effect liability normally associated with more promiscuous VGSC blocking drugs. The compounds of the invention are potent inhibitors of PN3 channels.

Ohkawa *et al.* have described a class of cyclic ethers that are of use as sodium channel blockers (U.S. Patent No. 6,172,085).

Currently, gabapentin is the market leading treatment for neuropathic pain. As with epilepsy, its mechanism of action for pain is unknown. It is a very safe, easy to use drug, which contributes to its sales. Efficacy for neuropathic pain is not impressive, as few as only 30% of patients respond to gabapentin treatment. Carbamazepine is also used to treat neuropathic pain.

5

10

15

20

25

30

In view of the limited number of agents presently available and the low levels of efficacy of the available agents, there is a pressing need for compounds that are potent, specific inhibitors of ion channels implicated in neuropathic pain. The present invention provides such compounds, methods of using them, and compositions that include the compounds.

SUMMARY OF THE INVENTION

It has now been discovered that pyrazole-amides and -sulfonamides are potent inhibitors of sodium channels. In the discussion that follows, the invention is exemplified by reference to the inhibition of sodium channels that are localized in the peripheral nervous system, and in particular those inhibitors that are selective inhibitors of PN3, and are useful for treating neuropathic pain through the inhibition of sodium ion flux through channels that include the PN3 subunit. The focus of the discussion is for clarity of illustration only.

The compounds and methods of the present invention are useful for treating diseases in which blocking or inhibiting one or more PN3 ion channel provides relief from the disease. Of particular interest is the use of the compounds and methods of the invention for treating pain and central or peripheral nervous system disorders. The present invention is of use for treating both inflammatory and neuropathic pain.

The present invention provides compounds which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides compounds, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain.

In one aspect, the present invention provides compounds according to Formula I:

(I)

or a pharmaceutically acceptable salt thereof. In Formula I, the symbols R^1 and R^3 are independently selected from hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_4) haloalkyl, (C_1-C_6) heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl. The symbol R^2 represents hydrogen, (C_1-C_4) alkyl, (C_1-C_7) cycloalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, or heteroaryl (C_1-C_4) alkyl;

The symbol Y is a member selected from:

5

10

15

20

25

30

wherein X is a member selected from O, S and NR⁸. The symbol R⁸ represents hydrogen, cyano, nitro, alkyl, acyl, aryl or SO₂R⁹. R⁹ is selected from alkyl, aryl, heteroaryl and heterocycloalkyl. The symbols R⁴ and R⁵ independently represent hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl, with the proviso that if R⁴ is hydrogen, R⁵ is not hydrogen. R⁴ and R⁵ taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring. The symbol R⁶ represents hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl or (C₁-C₆)heteroalkyl. R⁷ is selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and and R⁶ and R⁷ together with the atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

In another aspect, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound provided above.

In yet another aspect, the present invention provides a method for inhibiting ion flux through voltage dependent sodium channels, comprising contacting a cell containing the target ion channels with a compound that comprises a pyrazolyl moiety, such as the compounds of Formula I.

In still another aspect, the present invention provides a method for the treatment of diseases through inhibition of ion flux through voltage dependent sodium channels, the method comprising treating the host with an effective amount of a sodium

channel inhibiting compound comprising a pyrazolyl moiety, such as a compound of Formula I.

Other objects, advantages and embodiments of the invention will be apparent from review of the detailed description that follows.

5

10

15

20 .

25

30

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a table displaying structures of representative compounds of the invention.

DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS

Definitions:

The term "pain" refers to all categories of pain, including pain that is described in terms of stimulus or nerve response, e.g., somatic pain (normal nerve response to a noxious stimulus) and neuropathic pain (abnormal response of a injured or altered sensory pathway, often without clear noxious input); pain that is categorized temporally, e.g., chronic pain and acute pain; pain that is categorized in terms of its severity, e.g., mild, moderate, or severe; and pain that is a symptom or a result of a disease state or syndrome, e.g., inflammatory pain, cancer pain, AIDS pain, arthropathy, migraine, trigeminal neuralgia, cardiac ischaemia, and diabetic neuropathy (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et al., eds., 12th ed. 1991); Williams et al., J. of Medicinal Chem. 42:1481-1485 (1999), herein each incorporated by reference in their entirety).

"Somatic" pain, as described above, refers to a normal nerve response to a noxious stimulus such as injury or illness, e.g., trauma, burn, infection, inflammation, or disease process such as cancer, and includes both cutaneous pain (e.g., skin, muscle or joint derived) and visceral pain (e.g., organ derived).

"Neuropathic" pain, as described above, refers to pain resulting from injury to or chronic changes in peripheral and/or central sensory pathways, where the pain often occurs or persists without an obvious noxious input.

"Biological medium," as used herein refers to both *in vitro* and *in vivo* biological milieus. Exemplary *in vitro* "biological media" include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. *In vivo* applications are generally performed in mammals, preferably humans.

"Compound of the invention," as used herein refers to the compounds discussed herein, pharmaceutically acceptable salts and prodrugs of these compounds.

"Inhibiting" and "blocking," are used interchangeably herein to refer to the partial or full blockade of a PN3 channel by a compound of the invention, which leads to a decrease in ion flux either into or out of a cell in which a PN3 channel is found.

5

10

15

20

25

30

Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents which would result from writing the structure from right to left, e.g., -CH₂O-is intended to also recite -OCH₂-; -NHS(O)₂- is also intended to represent. -S(O)₂HN-, etc.

The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (*i.e.* C₁-C₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. The term "alkyl," unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as "heteroalkyl." Alkyl groups, which are limited to hydrocarbon groups are termed "homoalkyl".

The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH₂CH₂CH₂-, and further includes those groups described below as "heteroalkylene." Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.

The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

The term "amino" refers to -NRR' in which R and R' are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

5

10

15

25

30

The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2,-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH₃)-CH₃. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the term "heteroalkylene" by itself or as part 20 of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH₂-CH₂-S-CH₂-CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula $-C(O)_2R'$ - represents both $-C(O)_2R'$ - and $-R'C(O)_2$ -.

In general, an "acyl" or "acyl substituent" is also selected from the group set forth above. As used herein, the term "acyl substituent" refers to groups attached to, and fulfilling the valence of a carbonyl carbon that is either directly or indirectly attached to the nucleus of the compounds of the present invention.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the

molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1 –(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, 1-pyrrolidine, 2-pyrrolidine, 3-pyrrolidine and the like.

5

10

15

20

25

30

The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C₁-C₄)alkyl" is meant to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3pyrrolyl, 1-pyrazole, 3-pyrazolyl, 4-pyrazole, 5-pyrazole, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 2-benzthiazole, 2-benzoxazole, 5-indolyl, 1-isoquinolyl, 5isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

For brevity, the term "aryl" when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been

replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).

Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl" and "heteroaryl") include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

5

Substituents for the alkyl, and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generally referred to as "alkyl substituents" and "heteroalkyl substituents," respectively, and they can be one or more of a variety of groups selected from, but not limited to: -hydrogen, -OR', =O, =NR'", =N-10 OR', -NR'R", -SR', -halogen, -SiR'R"R", -OC(O)R', -C(O)R', -CO₂R', -CONR'R", -OC(O)NR'R", -NR'C(O)R", -NR"'-C(O)NR'R", -NR'C(O)2R", -NR"'- $C(NR'R'')=NR''', -NR'''-C(NR'R'')=NR''', -S(O)R', -S(O)_2R', -S(O)_2NR'R'',$ -NR'SO₂R", -NR"'SO₂NR'R" -CN, -R' and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R", R" each 15 preferably independently refer to hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, (e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups), substituted or unsubstituted heteroaryl and substituted or unsubstituted arylalkyl. R"" refers to hydrogen, alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, 20 substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, -CN, -NO2 and -S(O)₂R'. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R" and R"" groups when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 25 7-membered ring. For example, -NR'R" is meant to include, but not be limited to, 1pyrrolidinyl, 1-piperidinyl, 1-piperazinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF₃ and -CH₂CF₃) and acyl (e.g., -C(O)CH₃, -C(O)CF₃, -30 $C(O)CH_2OCH_3$, and the like).

Similar to the substituents described for the alkyl radical, the aryl substituents and heteroaryl substituents are generally referred to as "aryl substituents" and "heteroaryl substituents," respectively and are varied and selected from, for example:

hydrogen, -OR', -C=NR'"'NR'R", -NR'"SO2NR'R", -NR'R", -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', $-CO_2R'$, -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR"'-C(O)NR'R", $-NR"C(O)_2R'$, -NR"'-C(NR'R")=NR"'', -S(O)R', $-S(O)_2R'$, $-S(O)_2R'$, S(O)2NR'R", -NR"SO2R', -CN and -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alkoxy, and 5 fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R" and R" each preferably independently refer to hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, (e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups), substituted or unsubstituted heteroaryl and substituted or unsubstituted arylalkyl. R"" refers to 10 hydrogen, alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, -CN, -NO2 and -S(O)₂R'. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R" and R"" groups when more than one of these groups is present. When R' and R" are attached to 15 the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include, but not be limited to, 1pyrrolidinyl, 1-piperidinyl, 1-piperazinyl and 4-morpholinyl.

Two of the aryl substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')q-U-, 20 wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH₂)_r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds 25 of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')s-X-(CR"R")d-, where s and d are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-. The substituents R, R', R" and R" are preferably independently selected 30 from hydrogen or substituted or unsubstituted (C1-C6)alkyl.

As used herein, the term "heteroatom" includes oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

The symbol "R" is a general abbreviation that represents a substituent group that is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl groups.

5

10

20

25

30

The symbol \sim , whether utilized as a bond or displayed perpendicular to a bond indicates the point at which the displayed moiety is attached to the remainder of the molecule, solid support, etc.

The term "pharmaceutically acceptable salts" includes salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the

salts are equivalent to the parent form of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (³H), iodine-125 (¹²⁵I) or carbon-14 (¹⁴C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

Description of the Embodiments

5

10

15

30

I. INHIBITORS OF VOLTAGE-DEPENDENT SODIUM CHANNELS

In one aspect, the present invention provides compounds having the formula:

$$\begin{array}{ccc} R_{N}^{1} & R^{2} \\ Y & N \\ R^{3} \end{array} \tag{I}$$

or a pharmaceutically acceptable salt thereof. In Formula I, the symbols R^1 and R^3 independently represent hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_4) haloalkyl, (C_1-C_6) heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl. R^2 is a moiety selected from hydrogen, (C_1-C_4) alkyl, (C_1-C_7) cycloalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, and heteroaryl (C_1-C_4) alkyl.

The symbol Y represents a member selected from:

5

10

15

20

$$\frac{1}{\sqrt{R^4}}$$
; $\frac{1}{\sqrt{R^4}}$; $\frac{1}{\sqrt{R^4}}$; $\frac{1}{\sqrt{R^4}}$; $\frac{1}{\sqrt{R^4}}$; and $\frac{1}{\sqrt{R^4}}$; and $\frac{1}{\sqrt{R^4}}$; and $\frac{1}{\sqrt{R^4}}$; and $\frac{1}{\sqrt{R^4}}$; $\frac{1}{\sqrt{R^4}$

wherein X is selected from O, S and NR⁸. The symbol R⁸ represents hydrogen, cyano, nitro, alkyl, acyl, aryl or SO₂R⁹. R⁹ is selected from alkyl, aryl, heteroaryl and heterocycloalkyl.

R⁴ and R⁵ are independently selected from hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl, with the proviso that if R⁴ is hydrogen, R⁵ is not hydrogen. R⁴ and R⁵ taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

The symbol R^6 represents hydrogen, (C_1-C_6) alkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl or (C_1-C_6) heteroalkyl; and R^7 is selected from (C_1-C_7) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_7) alkenyl, (C_1-C_6) heteroalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl, amino, alkoxy, (C_3-C_8) heterocycloalkyl and amino (C_1-C_5) alkyl. R^6 and R^7 together with the atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

In a presently preferred embodiment Y is a member selected from:

$$\mathbb{R}^{5}$$
; and \mathbb{R}^{7}

25 in which R⁴, R⁵, R⁶, R⁷, and X are as described above.

In another exemplary embodiment, the invention provides a compound having a structure according to Formula II:

in which R^1 , R^2 , R^3 , and Y are as described above. In this embodiment, R^1 and R^3 are preferably each independently selected from hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_4) haloalkyl and (C_1-C_5) heteroalkyl. R^2 is preferably selected from aryl and heteroaryl; and X is preferably O.

In a further exemplary embodiment, R^4 and R^5 taken together with the nitrogen to which they are attached form a ring system such as that set forth below:

5

15

20

25

$$N-R^{12}$$
; and $NR^{13}R^{14}$

In another preferred embodiment, R³ is hydrogen; R⁴ is selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl and heteroaryl(C₁-C₄)alkyl; and R⁵ is selected from hydrogen or alkyl. Alternatively, R⁴ and R⁵ taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocycloalkyl ring.

In yet a further preferred embodiment, the invention provides a compound in which R⁴ is a member selected from:

$$\label{eq:continuous_problem} \begin{picture}(100,0) \put(0,0){\line(1,0){100}} \put(0,0){\line(1,$$

wherein n is an integer from 0 to 4; and k is an integer from 1 to 3. The symbols R^{2a} and R^{2b} are independently selected from hydrogen and (C_1-C_4) alkyl, and R^{2a} and R^{2b} taken together with the carbon atom to which they are attached optionally form a 3- to 8-membered carbocyclic or heterocycloalkyl ring.

The symbol M represents a moiety that is selected from NR¹⁰, O and S, wherein R¹⁰ is selected from hydrogen, (C₁-C₆) alkyl, (C₁-C₈) heteroalkyl aryl, heteroaryl and (C₃-C₈) cycloalkyl. A, B, D, E and G are independently moieties selected from N, Noxide and CR¹¹, with the proviso that at most three of A, B, D, E and G is N; and at most one of A, B, D, E and G is N-oxide.

R¹¹ is a member selected from hydrogen, halo, amino, hydroxy, cyano, nitro, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)heteroalkyl, aryl, heteroaryl, (C₃-C₈)heterocycloalkyl, alkoxy, acyl, -C(NR¹²)R¹³, -SO₂R¹⁵, -SO₂NR¹³R¹⁴, -NR¹²SOR¹⁵,

-NR¹²SO₂NR¹³R¹⁴, -NR¹²C(N-CN)NR¹³R¹⁴, -NR¹²C(N-SO₂R¹⁵)NR¹³R¹⁴, -NR¹²C(N-COR¹⁵)NR¹³R¹⁴, -CONR¹³R¹⁴, -NR¹²(C=CH-NO₂)NR¹³R¹⁴, -NR¹²CONR¹³R¹⁴, -NR¹²COOR¹⁵, -OCONR¹³R¹⁴, and R¹¹ and R^{2a} taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl group with the proviso that A is CR¹¹.

 R^{11a} is selected from $(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_7)$ cycloalkyl, $(C_3\text{-}C_8)$ heterocycloalkyl, aryl and heteroaryl. The symbols R^{12} , R^{13} and R^{14} independently represent hydrogen, $(C_1\text{-}C_8)$ alkyl, $(C_3\text{-}C_7)$ cycloalkyl, $(C_1\text{-}C_8)$ heteroalkyl, aryl, heteroaryl, $(C_3\text{-}C_8)$ heterocycloalkyl, aryl $(C_1\text{-}C_4)$ alkyl, heteroaryl $(C_1\text{-}C_4)$ alkyl, amino $(C_1\text{-}C_4)$ alkyl and when R^{13} and R^{14} are attached to the same nitrogen atom, they are optionally combined to form a 5-, 6- or 7-membered ring.

 R^{15} is selected from (C_1-C_8) alkyl, (C_3-C_8) cycloalkyl, (C_1-C_8) heteroalkyl, aryl, heteroaryl and (C_3-C_8) heterocycloalkyl

When R^4 has a cyclic structure set forth above, R^1 and R^3 are preferably each members independently selected from hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_4) haloalkyl and (C_1-C_5) heteroalkyl; and X is O. R^2 is a preferably a member selected from aryl or heteroaryl.

In yet another preferred embodiment, the invention provides a compound in which R⁴ has a structure according to Formula III:

$$(CR^{2a}R^{2b}) \xrightarrow{T^4} W_{R^{15}}$$

$$T^1 \xrightarrow{T^2} T^3$$
(III).

20

25

30

5

10

. 15

In Formula III, W is preferably selected from S, SO or SO₂ or a single bond. SO₂ is presently most preferred. The symbol R^{15} represents a moiety selected from (C_1-C_4) alkyl, (C_1-C_6) alkenyl, (C_3-C_7) cycloalkyl, aryl, heteroaryl, (C_1-C_8) heteroalkyl, $NR^{16}R^{17}$. R^{16} and R^{17} are independently selected from hydrogen, (C_1-C_4) alkyl, (C_1-C_7) cycloalkyl, (C_1-C_8) heteroalkyl, (C_3-C_8) heterocycloalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl, amino (C_1-C_4) alkyl, with the proviso that when R^{15} is amino W is SO₂;

The symbols T^1 , T^2 , T^3 and T^4 are each independently selected from hydrogen, halo, amino, cyano, nitro, (C_1-C_4) alkyl, (C_3-C_8) cycloalkyl, (C_1-C_4) haloalkyl, alkoxy, fluoro(C_1-C_4)alkoxy, (C_1-C_7) cycloalkyl, (C_1-C_7) heteroalkyl, aryl and heteroaryl.

 T^1 and T^2 taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T^2 and T^3 taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T^3 and T^3 taken together with the atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T^4 and T^4 and T^4 taken together with the atoms to which they are attached optionally form a 4-to 8-membered carbocyclic or heterocycloalkyl ring.

In a preferred embodiment, R^1 and R^3 are each members independently selected from hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_4) haloalkyl or (C_1-C_5) heteroalkyl; and X is O. R^2 is preferably a member selected from aryl or heteroaryl.

Representative compounds of the invention are set forth in Example 24 and FIG. 1. Activities towards PN3 of selected compounds of the invention are provided in Table 1. The compound numbers in Table 1 are cross-referenced to the compound numbers set forth in the Example and figures.

15

10

5

Table 1

Compound #	Activity in Flux Assay
20	+++
23	++
39	++1-
114	+
154	+++
323	+++
411	+++
414	+++
444	++
449	+++
480	+++
1054	+++
1175	++

 $(+++0.1-4 \mu M; ++4.1-10 \mu M; +10.1-30 \mu M)$

Also within the scope of the present invention are compounds of the invention that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homologs of the compounds of the invention or reactive analogues thereof. The poly- and multi-valent species can be assembled from a single species or more than one species of the invention. For example, a dimeric construct can be "homodimeric" or "heterodimeric." Moreover, poly- and multi-valent constructs in which a compound of the invention or a reactive analogue thereof, is attached to an oligomeric or polymeric framework (e.g., polylysine, dextran, hydroxyethyl starch and the like) are within the scope of the present invention. The framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of the invention). Moreover, the framework can be derivatized with a single species of the invention or more than one species of the invention.

5

10

15

20

25

30

Moreover, the present invention includes compounds within the motif set forth in Formula I, which are functionalized to afford compounds having water-solubility that is enhanced relative to analogous compounds that are not similarly functionalized. Thus, any of the substituents set forth herein can be replaced with analogous radicals that have enhanced water solubility. For example, it is within the scope of the invention to, for example, replace a hydroxyl group with a diol, or an amine with a quaternary amine, hydroxy amine or similar more water-soluble moiety. In a preferred embodiment, additional water solubility is imparted by substitution at a site not essential for the ion channel activity of the compounds set forth herein with a moiety that enhances the water solubility of the parent compounds. Methods of enhancing the water-solubility of organic compounds are known in the art. Such methods include, but are not limited to, functionalizing an organic nucleus with a permanently charged moiety, e.g., quaternary ammonium, or a group that is charged at a physiologically relevant pH, e.g. carboxylic acid, amine. Other methods include, appending to the organic nucleus hydroxyl- or amine-containing groups, e.g. alcohols, polyols, polyethers, and the like. Representative examples include, but are not limited to, polylysine, polyethyleneimine, poly(ethyleneglycol) and poly(propyleneglycol). Suitable functionalization chemistries and strategies for these compounds are known in the art. See, for example, Dunn, R.L., et al., Eds. POLYMERIC DRUGS AND DRUG DELIVERY SYSTEMS, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991.

Preparation of Sodium Channel Inhibitors

5

10

20

25

Compounds of the present invention may be prepared using starting materials readily available from commercial suppliers or known intermediates. Examples of starting materials available from commercial suppliers include, but are not limited to, 3-methyl-2-phenylpyrazole-4-carboxylic acid, 1-phenyl-5-propyl-1H-pyrazole-4-carboxylic acid, 2-(4-carboxylic acid, 1-4-chlorophenyl)-5-propyl-1H-pyrazole-4-carboxylic acid, 2-(4-chlorophenyl)-3-trifluoromethyl)pyrazole-4-carboxylic acid, 1-4-(4-chlorophenyl)-1,3-thiazole-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid, 5-fluoro-1-phenylpyrazole-4-carboxylic acid and 1-(4-fluorophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid. Scheme 1 sets forth an exemplary synthetic scheme for the preparation of known intermediates used to prepare compounds of the invention.

$$F_{3}C \xrightarrow{\qquad \qquad \qquad } F_{3}C \xrightarrow{\qquad \qquad } F_{3}C \xrightarrow{\qquad \qquad } CF_{3}$$

$$\xrightarrow{\qquad \qquad } F_{3}C \xrightarrow{\qquad \qquad } CF_{3}$$

$$\xrightarrow{\qquad \qquad } F_{3}C \xrightarrow{\qquad \qquad } CF_{3}$$

$$\xrightarrow{\qquad \qquad } CF_{3} \xrightarrow{\qquad \qquad } CF_{3}$$

$$\xrightarrow{\qquad \qquad } CF_{3} \xrightarrow{\qquad \qquad } CF_{3} \xrightarrow{\qquad \qquad } CF_{3}$$

Scheme 1

In Scheme 1, anhydride a is contacted with allyl ether b to form adduct c.

The pyrazole ring system d is formed by contacting adduct c with hydrazine or a hydrazine derivative. The trifluoromethyl group of the pyrazole ketone d is removed by treatment with base to afford the carboxylic acid e.

Numerous routes are available for elaborating the carboxylic acid moiety of intermediates of the invention. In an exemplary procedure, the pyrazole carboxylic acid (compound f; Scheme 2) is activated via conversion to the carboxylic acid chloride (compound g; Scheme 2) and made to react with an amine (e.g.; HNR⁴R⁵) in an organic solvent such as dichloromethane or tetrahydrofuran in the presence of a base such as triethylamine or pyridine to give an amide of Formula I where Y is:

and X is O (compound h; Scheme 2). One skilled in the art will recognize that an amide of the invention may be converted to a thioamido (i.e.; X is S) by treatment with Lawesson's reagent or other methods known in the literature.

Scheme 2

Compounds of the present invention may also be prepared as shown in Schemes 3-6. In Scheme 3, the pyrazole amine (compound i) is made to react with a carboxylic acid chloride (e.g.; R⁷COCl) using similar conditions described above to give

 $\label{eq:polynomial} N = \sum_{N=-\infty}^{Z} R^7$ the amide of formula I where Y is R^6 , R^6 is H and Z is O.

Scheme 3

15

20

5

10

In Scheme 4, the pyrazole amine (i) may be made to react with an isocyanate in an organic solvent such as dichloromethane or tetrahydrofuran to give the

urea (compound k) where Y is R^6 , R^6 is H, Z is O and R^7 is amino. Alternatively, the pyrazole amine (compound i) may be made to react with an isothiocyanate to give a thiourea (i.e.; Z is S).

Scheme 4

In Scheme 5, the pyrazole amine (i) may be made to react with the

oxazolidinone intermediate (compound l) in an organic solvent such as tetrahydrofuran,
acetonitrile or n-butanol, typically at elevated temperature (50-100°C), to give the
sulfenyl urea. Methods used to prepare oxazolidinone are described in the literature.

Scheme 5

10

In Scheme 6, the pyrazole amine may be made to react with the phenoxy intermediate in an organic solvent such as tetrahydrofuran, acetonitrile or n-butanol, typically at elevated temperature (50-100°C), to give the cyanoguanidine. Methods used to prepare the phenoxy intermediate are described in the literature.

15

Scheme 6

II. ASSAYS FOR BLOCKERS OF SODIUM ION CHANNELS

20

25

PN3 monomers as well as PN3 alleles and polymorphic variants are subunits of sodium channels. The activity of a sodium channel comprising PN3 subunits can be assessed using a variety of *in vitro* and *in vivo* assays, *e.g.*, measuring current, measuring membrane potential, measuring ion flux, *e.g.*, sodium or guanidinium, measuring sodium concentration, measuring second messengers and transcription levels, and using *e.g.*, voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.

A number of experimental models in the rat are appropriate for assessing the efficacy of the compounds of the invention. For example, the tight ligation of spinal nerves described by Kim et al., Pain 50: 355-363 (1992) can be used to experimentally determine the effect of the compounds of the invention on a PN3 channel. For example, a sodium channel blockade in vitro assay can be used to determine the effectiveness of compounds of Formula I as sodium channel blockers in an in vitro model by the inhibition of compound action potential propagation in isolated nerve preparations (Kourtney and Stricharz, Local Anesthetics, Springer-Verlag, New York, 1987). The mechanical allodynia in vivo assay is also of use in determining the efficacy of compounds of the invention (Kim and Chung Pain 50:355 (1992)). Mechanical sensitivity can be assessed using a procedure described by Chaplan et al., J. Neurosci. Methods 53: 55-63 (1994). Other assays of use are known to those of skill in the art. See, for example, Loughhead et al., U.S. Patent No. 6,262,078.

10

15

20

25

30

Inhibitors of the PN3 sodium channels can be tested using biologically active recombinant PN3, or naturally occurring TTX-resistant sodium channels, or by using native cells, like cells from the nervous system expressing a PN3 channel. PN3 channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell. In such assays, PN3 is expressed alone to form a homomeric sodium channel or is co-expressed with a second subunit (e.g., another PN3 family member) so as to form a heteromeric sodium channel. Exemplary expression vectors include, but are not limited to, PN3-pCDNA3.1. The PN3 channel is stably expressed in mammalian expression systems.

Inhibition can be tested using one of the *in vitro* or *in vivo* assays described above. Samples or assays that are treated with a potential sodium channel inhibitor or activator are compared to control samples without the test compound, to examine the extent of inhibition. Control samples (untreated with activators or inhibitors) are assigned a relative sodium channel activity value of 100. Inhibition of channels comprising PN3 is achieved when the sodium channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%. Compounds that decrease the flux of ions will cause a detectable decrease in the ion current density by decreasing the probability of a channel comprising PN3 being open, by decreasing conductance through the channel, decreasing the number of channels, or decreasing the expression of channels.

Changes in ion flux may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing the sodium channel. A preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltage-clamp and patch-clamp techniques, using the "cell-attached" mode, the "inside-out" mode, the "outside-out" mode, the "perforated cell" mode, the "one or two electrode" mode, or the "whole cell" mode (see, e.g., Ackerman et al., New Engl. J. Med. 336: 1575-1595 (1997)). Whole cell currents are conveniently determined using the standard methodology (see, e.g., Hamil et al., Pflugers. Archiv. 391: 85 (1981). Other known assays include: radiolabeled rubidium flux assays and fluorescence assays using voltage-sensitive dyes (see, e.g., Vestergarrd-Bogind et al., J. Membrane Biol. 88: 67-75 (1988); Daniel et al., J. Pharmacol. Meth. 25: 185-193 (1991); Holevinsky et al., J. Membrane Biology 137: 59-70 (1994)). Assays for compounds capable of inhibiting or increasing sodium flux through the channel proteins can be performed by application of the compounds to a bath solution in contact with and comprising cells having a channel of the present invention (see, e.g., Blatz et al., Nature 323: 718-720 (1986); Park, J. Physiol. 481: 555-570 (1994)). Generally, the compounds to be tested are present in the range from about 1 pM to about 100 mM, preferably from about 1 pM to about 1 μ M.

5

10

15

20

25

30

The effects of the test compounds upon the function of the channels can be measured by changes in the electrical currents or ionic flux or by the consequences of changes in currents and flux. Changes in electrical current or ionic flux are measured by either increases or decreases in flux of ions such as sodium or guanidinium ions (see, e.g., Berger et al., U.S. Patent No. 5,688,830). The cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by radio-labeling of the ions. Consequences of the test compound on ion flux can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test compound on the channels of this invention. The effects of a test compound can be measured by a toxin-binding assay. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers, changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as Ca²⁺, or cyclic nucleotides.

High throughput screening (HTS) is of use in identifying promising candidates of the invention. Physiologically, Na channels open and close on a ms timescale. To overcome the short time in which channels are open the HTS assay can be run in the presence of an agent that modifies the gating of the channel, such as deltamethrin. This agent modifies the gating of Na channels and keeps the pore open for extended periods of time. In addition, while Na channels are primarily selective for Na, other monovalent cations can permeate the channel.

The specificity and effect of the PN3 blocking agents of the invention can also be assayed against non-specific blockers of PN3, such as tetracaine, mexilitine, and flecainide.

III. PHARMACEUTICAL COMPOSITIONS OF SODIUM CHANNEL OPENERS

In another aspect, the present invention provides pharmaceutical

compositions comprising a pharmaceutically acceptable excipient and a pyrazole, such as
a compound according to Formula I.

Formulation of the Compounds (Compositions)

5

10

20

25

30

The compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. Accordingly, the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and a neutral compound of the invention or a pharmaceutically acceptable salt thereof.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

5

10

15

20

25

30

The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package

containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

10 IV. METHODS FOR INHIBITING ION FLOW IN VOLTAGE-DEPENDENT SODIUM CHANNELS

In yet another aspect, the present invention provides methods for decreasing ion flow through voltage dependent sodium channels in a cell, comprising contacting a cell containing the target ion channels with a sodium channel-inhibiting amount of a pyrazole, such as a compound of Formula I.

The methods provided in this aspect of the invention are useful for the diagnosis of conditions that can be treated by inhibiting ion flux through voltage-dependent sodium channels, or for determining if a patient will be responsive to therapeutic agents, which act by inhibiting sodium channels.

20

25

15

5

V. METHODS FOR TREATING CONDITIONS MEDIATED BY VOLTAGE-DEPENDENT SODIUM CHANNELS

In still another aspect, the present invention provides a method for the treatment of a disorder or condition through inhibition of a voltage-dependent sodium channel. In this method, a subject in need of such treatment is administered an effective amount of a pyrazole compound, such as a compound according to Formula I. In a preferred embodiment, the compounds provided herein are used to treat a disorder or condition by inhibiting an ion channel of the voltage gated sodium channel family, *e.g.*, PN3.

The compounds provided herein are useful as sodium channel inhibitors and find therapeutic utility via inhibition of voltage-dependent sodium channels in the treatment of diseases or conditions. The sodium channels that are typically inhibited are described herein as voltage-dependent sodium channels such as the PN3 sodium channels.

The compounds of the invention are particularly preferred for use in the treating, preventing or ameliorating pain or seizures. The method includes administering to a patient in need of such treatment, a therapeutically effective amount of a pyrazole compound, e.g., a compound of the invention or a pharmaceutically acceptable salt thereof.

5

10

15

20

25

30

The compounds, compositions and methods of the present invention are of particular use in treating pain, including both inflammatory and neuropathic pain.

Exemplary forms of pain treated by a compound of the invention include, postoperative pain, osteoarthritis pain, pain associated with metastatic cancer, neuropathy secondary to metastatic inflammation, trigeminal neuralgia, glossopharangyl neuralgia, adiposis dolorosa, burn pain, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, pain following stroke, thalamic lesions, radiculopathy, and other forms of neuralgic, neuropathic, and idiopathic pain syndromes.

Idiopathic pain is pain of unknown origin, for example, phantom limb pain. Neuropathic pain is generally caused by injury or infection of the peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.

Moreover, any sodium channel inhibitory substance possessed of satisfactory sodium channel inhibiting activity coupled with favorable intracranial transfer kinetics and metabolic stability is expected to show good efficacy in central nervous system (CNS) diseases and disorders such as central nervous system ischemia, central nervous system trauma (e.g. brain trauma, spinal cord injury, whiplash injury, etc.), epilepsy, seizures, neurodegenerative diseases (e.g. amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington's chorea, Parkinson's disease, diabetic neuropathy, etc.), vascular dementia (e.g. multi-infarct dementia, Binswanger's disease, etc.), manic-depressive psychosis, depression, schizophrenia, chronic pain, trigeminal neuralgia, migraine, ataxia, bipolar disorder, spasticity, mood disorders, psychotic disorders, hearing and vision loss, age-related memory loss, learning deficiencies, anxiety and cerebral edema.

In treatment of the above conditions, the compounds utilized in the method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily. A daily dose range of about 0.1 mg/kg to about 100 mg/kg is more typical. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

20

25

In the examples below, unless otherwise stated, temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature (typically a range of from about 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mmHg) with a bath temperature of up to 60°C; the course of reactions was typically followed by thin layer chromatography and reaction times are provided for illustration only; products exhibited satisfactory ¹H-NMR and/or LCMS data; yields (when provided) are for illustration only; and the following conventional abbreviations are also used: mp (melting point), L (liter), mL (milliliters), mmol (millimoles), g (grams), mg (milligrams), min (minutes), LCMS (liquid chromatography-mass spectrometry) and h (hours), PS (polystyrene), DIEA (diisopropylethylamine).

EXAMPLE 1

Preparation of 1-(3-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid

1,1,1,5,5,5-Hexafluoro-3-isobutoxymethylen-pentane-2,4-dione was prepared according to experimental procedures described in *Synthesis* **1990**, 347-350.

5

10

15

20

25

3-Chlorophenylhydrazine (1.04 g, 7.29 mmol) was added to a solution of 1,1,1,5,5,5-hexafluoro-3-isobutoxymethylen-pentane-2,4-dione (2.13 g, 7.29 mmol) in acetonitrile (3 mL) at 0 °C. The reaction mixture was warmed to room temperature, stirred for 16 h and concentrated under reduced pressure. The crude residue was treated with methanol (25 mL) and potassium hydroxide (2.00 g) and the reaction mixture refluxed for 18 h. The reaction mixture was concentrated under reduced pressure and the crude product was taken up in water, acidified with 6M hydrochloric acid and extracted with ethyl acetate (5 x 50 mL). The organic layers were collected, concentrated and crude product purified by column chromatography on silica gel to give 1-(3-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid. LCMS m/z = 288.9(M-H).

EXAMPLE 2

 $\label{lem:preparation} Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid-pyridine-4-ylamide$

1-(4-Chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carbonyl chloride (0.100 g, 0.324 mmol) was added to a solution of 4-aminopyridine (0.036 g, 0.387 mmol) and pyridine (0.078 mL, 0.969 mmol) in acetonitrile (10 mL). The reaction mixture was heated at 60 °C for 12 h, concentrated and the crude product was purified by column

chromatography on silica gel to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridine-4-ylamide. LCMS $m/z = 366.9 \text{ (M+H)}^+$.

EXAMPLE 3

5 Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methane sulfonyl-phenyl)-amide

1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.250 g, 0.808 mmol) was added to a solution of 3-methylsulfonylaniline hydrochloride (0.184 g, 0.889 mmol) and triethylamine (0.563 mL, 4.04 mmol) in acetonitrile (20 mL). The reaction mixture heated at 60 °C for 12 h, concentrated and crude product purified by column chromatography on silica gel to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methane sulfonyl-phenyl)-amide. ¹H-NMR (CD₃OD, 300 MHz) δ 8.37 (s, 1H), 8.17 (s, 1H), 7.97 (d, 1H, J = 8.5 Hz), 7.73 (d, 1H, J = 8.0 Hz), 7.59-7.66 (m, 3H), 7.51 (d, 2H, J = 8.8 Hz), 3.15 (s, 3H); LCMS m/z = 443.9 (M+H)⁺.

10

15

20

25

EXAMPLE 4

 $\label{lem:preparation} Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic \\ acid \ [2-(3-fluoro-phenyl)-ethyl]-amide$

1-(4-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carbonyl chloride (0.100 g, 0.324 mmol) was added to a solution of 2-(3-fluoro-phenyl) ethylamine (0.051 mL, 0.389 mmol) and triethylamine (0.135 mL, 0.972 mmol) in acetonitrile (10 mL). The reaction mixture stirred for 1 hr at room temperature, concentrated and crude product purified by column chromatography on silica gel to give 1-(4-chloro-phenyl)-5-

trifluoromethyl-1*H*-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide. LCMS $m/z = 412.0 \text{ (M+H)}^+$.

EXAMPLE 5

5 Preparation of 1-(3-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide)

Benzotriazole-1-yloxytris(dimethylamino)phosphonium

10

15

20

25

hexafluorophosphate (BOP) (0.083 g; 0.189 mmol) was added to a solution of 1-(3-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (0.050 g; 0.172 mmol), 3-trifluoromethyl benzylamine (0.030 g; 0.206 mmol) and triethylamine (0.072 mL; 0.516 mmol) in tetrahydrofuran (10 mL). The reaction mixture was stirred at room temperature for 4 h, concentrated and the crude product purified by column chromatography on silica gel to give 1-(3-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide. LCMS $m/z = 448.8 \, (M+H)^+$.

EXAMPLE 6

Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide)

2-4-difluoro-phenylamine (0.004 g; 0.029 mmL) was added to a suspension of 1-(4-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carbonyl chloride (0.010 g; 0.032 mmol) and PS-DIEA (0.1 g) in acetonitrile (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time PS-trisamine (0.1 g) was added to remove the excess acid chloride. After an additional 12 h of shaking, the reaction mixture was filtered and

concentrated to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide. LCMS m/z = 399.8 (M-H).

EXAMPLE 7

5 Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide

2-Fluoro-3-trifluoromethyl-phenylamine (0.007 g; 0.039 mmol) was added to a suspension of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.010 g; 0.032 mmol) and PS-DIEA (0.1g) in acetonitrile (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time PS-TSCl (0.2 g) high loading was added to remove the excess amine. After an additional 12 h of shaking, the reaction mixture was filtered and concentrated to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide. LCMS m/z = 449.9 (M-H).

10

15

20

EXAMPLE 8

 $\label{lem:preparation} Preparation of 1-(4-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic \\ acid 3-trifluoromethyl-benzylamide$

$$F_{3}C O H_{2}N + CF_{3}$$

$$PS-carbodiimide$$

$$CH_{3}CN$$

$$F_{3}C O H_{2}N + CF_{3}$$

$$F_{3}C O H_{3}CF_{3}$$

3-Trifluoromethyl benzylamine (0.014 mL, 0.100 mmole) was added to a suspension of 1-(4-fluoro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid (0.030 g; 0.109 mmol) and PS-Carbodiimide (0.2 g) in methylene chloride (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time the reaction mixture was filtered and concentrated to give 1-(4-fluoro-phenyl)-5-trifluoromethyl-1*H*-

pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide. LCMS m/z = 432.3 (M+H)⁺.

EXAMPLE 9

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine

Bromine (4.70 mL, 100 mmol) was added to a solution of 1-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide (1.20 g, 4.15 mmol) in 3M NaOH (100 mL). The reaction mixture was heated at 100 °C for 1 hour, cooled to room temperature and extracted with EtOAc (3 x 50 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (0.408 g, 38 %).

10

5

EXAMPLE 10

 $\label{lem:preparation} Preparation of 1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea$

15

20

Triphosgene (0.042 g, 0.140 mmol) was added to a solution of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (0.100 g, 0.382 mmol) and Na₂CO₃ (0.405 g, 3.82 mmol) in CH₂Cl₂/H₂O (50 mL, 1:1) and stirred at room temperature for 30 min. 3-Methanesulfonyl-phenylamine HCl (0.095 g, 0.458 mmol) was added to the reaction mixture, stirred at room temperature for 2 hrs, organic layer collected and aqueous layer extracted with EtOAc (3 x 25 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea (0.040 g, 22 %).

25

EXAMPLE 11

$$CI - \bigvee_{N}^{F_3C} + \bigvee_{CI}^{NH_2} + \bigcup_{CI}^{CI} - \bigcup_{N}^{F_3C} + \bigvee_{N}^{H} + \bigcup_{CI}^{H} - \bigcup_{CI}^{H} + \bigcup_{CI}^{H} - \bigcup_{C$$

Excess 3,4-dichlorophenylisocyanate was added to a solution of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (13.1 mg, 0.05 mmol) in THF (1 mL). The reaction was shaken overnight then the excess 3,4-dichlorophenylisocyanate was scavenged with PS-trisamine. The product (21.4 mg, 95%) was isolated by filtration and evaporation.

EXAMPLE 12

Preparation of 3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride

5

10

15

20

25

1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (3.00 g, 9.70 mmol) was added to 3-amino-benzenesulfonyl fluoride (1.87 g, 10.6 mmol) in CH₂Cl₂ (50 ml) containing pyridine (2.35 ml, 29.1 mmol). Reaction mixture stirred overnight at room temperature, concentrated under reduced pressure and crude product purified by column chromatography to give 3-{[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride (3.23 g, 74 %).

EXAMPLE 13

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide

Cyclopropyl amine (0.012 mL, 0.167 mmol) was added to 3-{[1-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride (0.025 g, 0.055 mmol) in CH₂Cl₂ (10 ml). Reaction mixture stirred overnight at room temperature, concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide (0.015 g, 55 %).

EXAMPLE 14

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- cyano-2-phenyl-isourea)-amide

5

10

15

20

25

Diphenyl N-cyanocarbonimidate (0.235 g, 0.984 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.250 g, 0.656 mmol) in CH₃CN (10 mL) and heated at 80 °C overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- cyano-2-phenyl-isourea)-amide (0.258 g, 75 %).

EXAMPLE 15

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid N'-methyl-cyanoguanidine

1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyano-2-phenyl-isourea)-amide (0.050 g, 0.095 mmol) was added to a solution of methyl amine (10 mL, 20 mmol, 2M in THF) and stirred overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid N'-methyl-cyanoguanidine (0.038 g, 88 %).

EXAMPLE 16

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- methylsulfone-2-phenyl-isourea)-amide.

Diphenyl N-methylsulfone-carbonimidate (0.573 g, 1.97 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.500 g, 1.31 mmol) in CH₃CN (20 mL) and heated at 80 °C for 2 days. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- methylsulfone-2-phenyl-isourea)-amide (0.700 g, 92 %).

EXAMPLE 17

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(N'-methylsulfone-N''-cyclopropyl-guanidino)-phenyl]-amide

1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methylsulfone-2-phenyl-isourea)-amide (0.025 g, 0.0432 mmol) was added to a solution of cyclopropyl amine (0.030 mL, 0.432 mmol) in THF (5 mL) and stirred overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(N'-methylsulfone-N"-cyclopropyl-guanidino)-phenyl]-amide (0.015 g, 65 %).

EXAMPLE 18

5

10

15

20

25

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide.

1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.100 g, 0.323 mmol) was added to 3-amino-boronic acid monohydrate (0.060 g, 0.388 mmol) in CH₂Cl₂ (5 ml) containing pyridine (0.078 ml, 0.970 mmol). Reaction mixture stirred 2 hours at 80 °C, concentrated under reduced pressure and crude product purified

by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide. (0.130 g, 98 %).

EXAMPLE 19

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-thiazol-2-yl-phenyl)-amide

5

10

15

20

25

$$CI$$
 CF_3
 O
 Pd
 (II)
 F_3C
 O
 H
 S
 N
 H
 S

Dichlorobis(triphenylphosphine)palladium (II) (0.002 g, 0.00244 mmol) was added to a degassed (N₂) mixture of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide (0.100 g, 0.244 mmol), Na₂CO₃ (0.052 g, 0.488 mmol), and 2-Bromo-thiazole (0.048 g, 0.292 mmol) in H₂O/toluene (1 mL/2 mL). Reaction mixture heated at 80 °C for 12 hours, cooled to room temperature and extracted with EtOAc (3 x 5 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-thiazol-2-yl-phenyl)-amide (0.074 g, 67 %).

EXAMPLE 20

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamide-phenyl)-amide.

Sulfamide (0.010 g, 0.105 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.020 g, 0.00525 mmol) in 1,4-dioxane (2 mL) and heated at 120 °C overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamide-phenyl)-amide (0.013 g, 54 %).

EXAMPLE 21

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylsulfamide-phenyl)-amide.

Dimethylsulfamoyl chloride (0.010 g, 0.105 mmol) was added to 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.025 g, 0.0656 mmol) in CH₃CN (2 mL) containing pyridine (0.016 mL, 0.196 mmol). Reaction mixture stirred overnight, concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylsulfamide-phenyl)-amide (0.019 g, 59 %).

EXAMPLE 22

14C Guanidinium Ion Influx Binding Assay

5

10

15

20

25

PN3 stably expressed in a host cell line were maintained in DMEM with 5% fetal bovine serum and 300 μ g/ml G-418. The cells were subcultured and grown to confluence in 96-well plates 24-48 h before each experiment. After the growth medium was removed, the cells were washed with warm buffer (25 mM Hepes-Tris, 135 mM choline chloride, 5.4 mM potassium chloride, 0.98 mM magnesium sulfate, 5.5 mM glucose, and 1 mg/ml BSA, pH 7.4) and incubated in buffer on a 36 °C slide warmer for approximately 10 minutes. Various concentrations of the test compounds or standard sodium channel blockers (10 μ M) and then deltamethrine (10 μ M) were added to each well. After the cells were exposed to deltamethrine for 5 minutes, 5 μ M of ¹⁴C-guanidinium was added, incubated with the radioligand (30-60 min), washed with ice-cold buffer, and dissolved in 0.1N sodium hydroxide. The radioactivity and the protein concentration of each cell lysate were determined by liquid scintillation counting and the protein assay using Pierce BCA reagent.

EXAMPLE 23

23.1 Mechanical Allodynia In vivo Assay

5

10

15

20

25

30

This assay determines the effectiveness of compounds of Formula I in relieving one of the symptoms in an *in vivo* model of neuropathic pain produced by spinal nerve ligation, namely mechanical allodynia.

Tactile allodynia was induced in rats using the procedures described by Kim and Chung, *Pain* 50: 355-363 (1992). Briefly, the rats were anesthetized with 2-5% inhaled isoflurane and maintained by 1% isoflurane. Each animal was then placed in a prone position, a 3 cm lateral incision was made, and the left paraspinal muscles separated from the spinous process at the L₄-S₂ level. The L₆ transverse process was then removed in order to visually identify the L₄-L₆ spinal nerves. The L₅ and L₆ spinal nerves were then individually isolated and tightly ligated with silk thread. The wound was then closed in layers by silk sutures. These procedures produced rats which developed a significant increase in sensitivity to mechanical stimuli that did not elicit a response in normal rats.

Mechanical sensitivity was assessed using a procedure described by Chaplan et al., J. Neurosci. Methods 53: 55-63 (1994). Briefly, a series of eight Von Frey filaments of varying rigidity strength were applied to the plantar surface of the hind paw ipsilaterial to the ligations with just enough force to bend the filament. The filaments were held in this position for no more than three seconds or until a positive allodynic response was displayed by the rat. A positive allodynic response consisted of lifting the affected paw followed immediately by licking or shaking of the paw. The order and frequency with which the individual filaments were applied were determined by using Dixon up-down method. Testing was initiated with the middle hair of the series with subsequent filaments being applied in consecutive fashion, either ascending or descending, depending on whether a negative or positive response, respectively, was obtained with the initial filament.

23.2 Thermal Hyperalgesia In vivo Assay

This assay determines the effectiveness of compounds in relieving one of the symptoms of neuropathic pain produced by unilateral mononeuropathy, namely thermal hyperalgesia.

The rats having had surgery as described above were assessed for thermal hyperalgesia sensitivity at least 5-7 days post-surgery. Briefly, the rats were placed

beneath inverted plexiglass cages upon an elevated glass platform and a radiant heat source beneath the glass was aimed at the plantar hindpaw. The duration of time before the hindpaw was withdrawn from the floor was measured to the nearest tenth of a second. The cutoff time for the heat stimulus was 40 seconds, and the light was calibrated such that this stimulus duration did not burn or blister the skin. Three latency measurements were taken for each hindpaw ipsilateral to the ligation in each test session, alternating left and right hindpaws, with greater than 1 minute intervals between tests.

23.3 Results

5

The results show that after oral administration the compounds of the invention produce efficacious anti-allodynic effects at doses less then or equal to 100 mg/kg. The results show that after IV administration the compounds of the invention produce efficacious anti-hyperalgesic effects at doses less than or equal to 30 mg/kg. Overall, the compounds of the present invention were found to be effective in reversing mechanical allodynia-like and thermal hyperalgesia-like symptoms.

EXAMPLE 24Example 24 sets forth representative compounds of the invention.

compound #	name	MZ
1	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	423
2	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (pyridin-2-ylmethyl)-amide	380
3	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (pyridin-3-ylmethyl)-amide	380
4	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (pyridin-4-ylmethyl)-amide	380
5	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,4,6-trichloro-phenyl)-amide	467
6	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,4-dichloro-benzylamide	447

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
7	carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-	429
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	461
8	carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	401
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
9	carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-	467
	amide	
10	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	455
10	carboxylic acid (biphenyl-3-ylmethyl)-amide	455
11	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	370
11	carboxylic acid (5-methyl-isoxazol-3-yl)-amide	370
10	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	355
12	carboxylic acid (1H-pyrazol-3-yl)-amide	333
13	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	380
15	carboxylic acid (4-cyano-2H-pyrazol-3-yl)-amide	300
. 14	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	383
14	carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide	
15	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	371
13	carboxylic acid (5-hydroxy-1H-pyrazol-3-yl)-amide	
16	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	356
10	carboxylic acid isoxazol-3-ylamide	
17	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	431
17	carboxylic acid (5-phenyl-2H-pyrazol-3-yl)-amide	
18	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	383
18	carboxylic acid (2,5-dimethyl-2H-pyrazol-3-yl)-amide	
19	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	448
	carboxylic acid (4-bromo-5-methyl-isoxazol-3-yl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
20	carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-	445
	amide	<u> </u>

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
21	carboxylic acid (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-	447
	3-yl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	366
22	carboxylic acid pyridin-3-ylamide	300
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	366
23	carboxylic acid pyridin-4-ylamide	300
24	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	447
24	carboxylic acid 3-trifluoromethyl-benzylamide	777
25	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	447
25	carboxylic acid 4-trifluoromethyl-benzylamide	447
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
26	carboxylic acid [2-(3-chloro-4-fluoro-phenyl)-4-cyano-	508
	2H-pyrazol-3-yl]-amide	
27	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
27	carboxylic acid (5-bromo-6-methyl-pyridin-2-yl)-amide	430
28	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	453
28	carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	-
29	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,5-	393
29	dimethoxy-phenyl)-ethyl]-amide	
30 ·	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	439
30	carboxylic acid 2,6-dimethoxy-benzylamide	
31	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 2,6-	379
31	dimethoxy-benzylamide	
32	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	432
32	carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	
33	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(1H-	372
, 33	indol-3-yl)-ethyl]-amide	
2/	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	375
34	4-carbonyl]-amino}-propionic acid methyl ester	
35	2-[(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-	315
33	propionic acid methyl ester	

36	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	417
	4-carbonyl]-amino}-propionic acid methyl ester	
37	4-Methyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	357
3.	amino]-pentanoic acid methyl ester	
38	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	451
30	4-carbonyl]-amino}-3-phenyl-propionic acid methyl ester	
39	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	391
3)	amino]-propionic acid methyl ester	
40	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	451
40	carboxylic acid (3-fluoro-5-trifluoromethyl-phenyl)-amide	.51
41	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-	391
71	fluoro-5-trifluoromethyl-phenyl)-amide	
	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	
42	4-carbonyl]-amino}-3-(1H-indol-3-yl)-propionic acid	490
	methyl ester	·
43	3-(1H-Indol-3-yl)-2-[(1-phenyl-5-propyl-1H-pyrazole-4-	430
-13	carbonyl)-amino]-propionic acid methyl ester	.50
44	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	453
	carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	.55
45	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-	393
15	dimethoxy-phenyl)-ethyl]-amide	
46	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	399
40	carboxylic acid (2-thiophen-2-yl-ethyl)-amide	
47.	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	339
47.	thiophen-2-yl-ethyl)-amide	
48	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	369
-10	carboxylic acid (furan-2-ylmethyl)-amide	
49	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (furan-	309
	2-ylmethyl)-amide	
50	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	394
	carboxylic acid (2-pyridin-2-yl-ethyl)-amide	
51	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	334
31	pyridin-2-yl-ethyl)-amide	334

52	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	448
32	carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	440
52	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1-	388
53	benzyl-pyrrolidin-3-yl)-amide	500
54	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	385
34	carboxylic acid (thiophen-2-ylmethyl)-amide	505
55	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid	325
33	(thiophen-2-ylmethyl)-amide	323
56	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
30	carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide	415
57	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1H-	359
57	benzoimidazol-2-ylmethyl)-amide	339
50	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	400
58	carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
50	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1-	340
59	ethyl-pyrrolidin-2-ylmethyl)-amide	340
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	394
60	carboxylic acid (2-pyridin-3-yl-ethyl)-amide	394
	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	334
. 61	pyridin-3-yl-ethyl)-amide	334
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	409
62	carboxylic acid (2-phenoxy-ethyl)-amide	409
	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	349
63	phenoxy-ethyl)-amide	349
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	414
64	carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide	717
65	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [3-(2-	354
65	oxo-pyrrolidin-1-yl)-propyl]-amide	354
	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid	395
66	(biphenyl-3-ylmethyl)-amide	393
67	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	515
	carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	313

68	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3,5-bis- trifluoromethyl-benzylamide	455
69	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 4-nitro-benzylamide	424
70	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 4-nitro- benzylamide	364
71	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-imidazol-1-yl-propyl)-amide	397
72	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3- imidazol-1-yl-propyl)-amide	337
73	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	373
74	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	313
75	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid cyclohexylmethyl-amide	385
76	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	325
77	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid isobutyl-amide	345
78	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid isobutyl-amide	285
79	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid indan-1-ylamide	405
80	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid indan- 1-ylamide	345
81	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid cyclopentylamide	357
82	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	297
83	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-morpholin-4-yl-ethyl)-amide	402

84	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide	342
85	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-dimethoxy-benzylamide	439
86	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3,5- dimethoxy-benzylamide	379
87	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	363
88	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3- trifluoromethyl-benzylamide	387
89	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-dimethylamino-ethyl)-amide	360
90	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2- dimethylamino-ethyl)-amide	300
91	{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-methyl-amino}-acetic acid ethyl ester	389
92	[Methyl-(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)- amino]-acetic acid ethyl ester	329
93	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- pyrrolidin-1-yl-methanone	343
94	(1-Phenyl-5-propyl-1H-pyrazol-4-yl)-pyrrolidin-1-yl- methanone	283
95	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- (3,4-dihydro-1H-isoquinolin-2-yl)-methanone	405
96	(3,4-Dihydro-1H-isoquinolin-2-yl)-(1-phenyl-5-propyl-1H-pyrazol-4-yl)-methanone	345
97	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid benzyl-ethyl-amide	407
98	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid benzyl- ethyl-amide	347
99	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- thiomorpholin-4-yl-methanone	375

100	(1-Phenyl-5-propyl-1H-pyrazol-4-yl)-thiomorpholin-4-yl-	315
100	methanone	
101	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	414
101	carbonyl]-pyrrolidine-2-carboxylic acid dimethylamide	
102	1-(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	354
102	pyrrolidine-2-carboxylic acid dimethylamide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	-
103	carboxylic acid (2-methoxy-benzyl)-(2-pyridin-2-yl-	514
	ethyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
104	carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-2-yl-	552
	ethyl)-amide	
****	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
105	carboxylic acid (4-fluoro-benzyl)-(2-pyridin-2-yl-ethyl)-	502
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
106	carboxylic acid (4-methyl-benzyl)-(2-pyridin-2-yl-ethyl)-	498
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
107	carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-3-yl-	552
	ethyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
108	carboxylic acid (3,4-dimethoxy-benzyl)-(1-phenyl-ethyl)-	543
	amide	
109	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	446
	carboxylic acid (2-cyano-ethyl)-phenethyl-amide	
110	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
	carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-4-yl-	552
	ethyl)-amide	
111	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	440
	carboxylic acid (5-chloro-benzooxazol-2-yl)-amide	
112	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	434
	carboxylic acid (3,5-dichloro-pyridin-2-yl)-amide	

112	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	400
113	carboxylic acid (5-chloro-pyridin-2-yl)-amide	400
114	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
114	carboxylic acid phenethyl-amide	393
115	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	394
113	carboxylic acid (2-pyridin-4-yl-ethyl)-amide	394
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
116	carboxylic acid (3-chloro-5-trifluoromethyl-pyridin-2-yl)-	468
	amide	
117	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	464
117	carboxylic acid (3-diethylcarbamoyl-phenyl)-amide	404
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
118	carboxylic acid [4-(5-methyl-isoxazol-3-ylsulfamoyl)-	525
•	phenyl]-amide	
110	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	399
119	carboxylic acid (2-chloro-phenyl)-amide	399
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
120	carboxylic acid (1-ethyl-2-methyl-1H-benzoimidazol-5-	447
	yl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
. 121	carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-	512
	amide	
122	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	471
122	carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	7/1
123	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	405
123	carboxylic acid (1H-indazol-6-yl)-amide	403
. 124	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	365
124	carboxylic acid phenylamide	303
125	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-	404
, 14J	diethylcarbamoyl-phenyl)-amide	707
126	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [4-(5-	465
126	methyl-isoxazol-3-ylsulfamoyl)-phenyl]-amide	-703

127	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2- chloro-phenyl)-amide	339
128	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1- ethyl-2-methyl-1H-benzoimidazol-5-yl)-amide	387
129	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-amide	452
130	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	411
131	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1H- indazol-6-yl)-amide	345
132	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid phenylamide	305
133	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-diethylcarbamoyl-phenyl)-amide	430
134	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]-amide	491
135	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	365
136	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-2-methyl-1H-benzoimidazol-5-yl)-amide	413
137	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-amide	478
138	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	437
139	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-indazol-6-yl)-amide	371
140	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenylamide	331
141	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid m-tolylamide	379
142	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-methoxy-phenyl)-amide	395

143	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	379
143	carboxylic acid benzylamide	3,7
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
144	carboxylic acid benzyl-methyl-amide	393
1.45	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	409
145	carboxylic acid 4-methoxy-benzylamide	409
146	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	424
140	carboxylic acid 3-nitro-benzylamide	727
147	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
147	carboxylic acid 3-methyl-benzylamide	373
148	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	527
140	4-carbonyl]-amino}-3-phenyl-propionic acid benzyl ester	327
149	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	451
149	4-carbonyl]-amino}-3-phenyl-propionic acid methyl ester	431
	2-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	
150	4-carbonyl]-amino}-3-phenyl-propionic acid tert-butyl	493
	ester	
,	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
151	carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-	429
	amide [.]	
152	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	390
132	carboxylic acid (3-cyano-phenyl)-amide	
153	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	422
133	carboxylic acid 4-dimethylamino-benzylamide	
154	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	443
154	carboxylic acid (3-methanesulfonyl-phenyl)-amide	
155	4-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	437
133	4-carbonyl]-amino}-benzoic acid ethyl ester	
156	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	467
	amino]-propionic acid benzyl ester	
157	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	391
15/	amino]-propionic acid methyl ester	~~~

158	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)- amino]-propionic acid tert-butyl ester	433
159	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2- cyclohexyl-1-hydroxymethyl-ethyl)-amide	369
160	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3- cyano-phenyl)-amide	, 330
161	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 4- dimethylamino-benzylamide	362
162	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	383
163	4-[(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]- benzoic acid ethyl ester	377
164	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid benzyl ester	493
165	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	417
166	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid tert-butyl ester	459
167	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-amide	395
168	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyano-phenyl)-amide	356
169	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-dimethylamino-benzylamide	388
170	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	409
171	4-[(1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)- amino]-benzoic acid ethyl ester	403
172	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide	465
173	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]- amide	461

	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	
174	(7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)-	473
	methanone	
. 175	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	463
175	carboxylic acid (3-trifluoromethyl-benzyloxy)-amide	105
176	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	291
170	benzylamide	201
177	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid tert-	257
177	butylamide	
178	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	305
170	phenethyl-amide	
179	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	297
175	cyclohexylmethyl-amide	
180	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	269
100	cyclopentylamide	
181	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	367
101	(biphenyl-3-ylmethyl)-amide	
182	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3,5-	427
102	bis-trifluoromethyl-benzylamide	
183	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3-	359
. 100	trifluoromethyl-benzylamide	
184	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	335
	(benzo[1,3]dioxol-5-ylmethyl)-amide	
185	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3,4-	359
	dichloro-benzylamide	
186	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	461
	carboxylic acid methyl-(3-trifluoromethyl-benzyl)-amide	
187	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	475
	carboxylic acid ethyl-(3-trifluoromethyl-benzyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	10-
188	carboxylic acid benzo[1,3]dioxol-5-ylmethyl-methyl-	437
	amide	<u></u>

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
189	carboxylic acid benzo[1,3]dioxol-5-ylmethyl-ethyl-amide	451
190	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	200
190	carboxylic acid methyl-thiophen-2-ylmethyl-amide	399
191	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	412
191	carboxylic acid ethyl-thiophen-2-ylmethyl-amide	413
192	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	461
192	carboxylic acid methyl-(4-trifluoromethyl-benzyl)-amide	401
193	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	405
193	carboxylic acid ethyl-(4-trifluoromethyl-benzyl)-amide	475
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
194	carboxylic acid benzo[1,3]dioxol-5-ylmethyl-(2-	494
-	dimethylamino-ethyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
· 195	carboxylic acid (2-dimethylamino-ethyl)-(3-	518
	trifluoromethyl-benzyl)-amide	
196	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	390
130	carboxylic acid benzylamide	390
197	1-(6-Ethoxy-pyridazin-3-yl)-5-trifluoromethyl-1H-	391
157	pyrazole-4-carboxylic acid benzylamide	391
. 198	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	402
. 150	carboxylic acid benzylamide	
199	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	390
133	carboxylic acid benzylamide	370
200	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	375
200	carboxylic acid benzylamide	373
201	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	413
201	carboxylic acid benzylamide	413
202	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	413
202	pyrazole-4-carboxylic acid benzylamide	413
203	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	345
200	benzylamide	J 4 J

204	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid tert-butylamide	356
205	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid tert-butylamide	347
206	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid tert-butylamide	368
207	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid tert-butylamide	356
208	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid tert-butylamide	341
209	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid tert-butylamide	379
210	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H- pyrazole-4-carboxylic acid tert-butylamide	379
211	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	311
212	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	404
213	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid phenethyl-amide	395
214	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	416
215	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	404
216	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	389
217	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	427
218	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H- pyrazole-4-carboxylic acid phenethyl-amide	427
219	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	359

220	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	396
	carboxylic acid cyclohexylmethyl-amide	370
201	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-	387
221	pyrazole-4-carboxylic acid cyclohexylmethyl-amide	307
222	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	408
222	carboxylic acid cyclohexylmethyl-amide	400
223	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	396
243	carboxylic acid cyclohexylmethyl-amide	390
224	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	381
224	carboxylic acid cyclohexylmethyl-amide	301
225	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
223	carboxylic acid cyclohexylmethyl-amide	417
226	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	419
220	pyrazole-4-carboxylic acid cyclohexylmethyl-amide	417
227	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	351
221	cyclohexylmethyl-amide	331
228	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	368
220	carboxylic acid cyclopentylamide	
229	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-	359
22)	pyrazole-4-carboxylic acid cyclopentylamide	
230	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	380
230	carboxylic acid cyclopentylamide	
231	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	368
	carboxylic acid cyclopentylamide	
232	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	353
	carboxylic acid cyclopentylamide	
233	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	391
	carboxylic acid cyclopentylamide	
234	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	391
	ругаzole-4-carboxylic acid cyclopentylamide	
/ 235	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	323
	cyclopentylamide	

236	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (biphenyl-3-ylmethyl)-amide	466
237	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	457
238	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (biphenyl-3-ylmethyl)-amide	478
239	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (biphenyl-3-ylmethyl)-amide	466
240	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (biphenyl-3-ylmethyl)-amide	451
241	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (biphenyl-3-ylmethyl)-amide	489
242	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	489
243	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	421
244	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	526
245	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl- benzylamide	517
246	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	538
247	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	526
248	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	511
249	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	549
250	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H- pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl- benzylamide	549

251	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	481
251	3,5-bis-trifluoromethyl-benzylamide	401
252	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
252	carboxylic acid 3-trifluoromethyl-benzylamide	436
253	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-	449
233	pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	449
254	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	470
234	carboxylic acid 3-trifluoromethyl-benzylamide	470
255	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
233	carboxylic acid 3-trifluoromethyl-benzylamide	430
256	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	443
230	carboxylic acid 3-trifluoromethyl-benzylamide	442
257	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	481
201	carboxylic acid 3-trifluoromethyl-benzylamide	401
258	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	481
238	pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	701
259	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	413
239	3-trifluoromethyl-benzylamide	415
260	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	434
200	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	757
	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-	
261	pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-	425
	ylmethyl)-amide	
262	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	446
202	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	
263	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	434
200	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	
264	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	
265	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	457
203	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	

	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	
266	pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-	457
	ylmethyl)-amide	
267	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	389
267	(benzo[1,3]dioxol-5-ylmethyl)-amide	369
268	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
208	carboxylic acid 3,4-dichloro-benzylamide	430
269	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-	449
209	pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	140
270	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-	470
	carboxylic acid 3,4-dichloro-benzylamide	
271	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
2/1	carboxylic acid 3,4-dichloro-benzylamide	
272	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	443
	carboxylic acid 3,4-dichloro-benzylamide	
273	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	481
213	carboxylic acid 3,4-dichloro-benzylamide	
274	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	481
2/7	pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	
275	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	413
. 2/3	3,4-dichloro-benzylamide	
276	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	367
	carboxylic acid pyrazin-2-ylamide	
277	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	435
277	carboxylic acid (4,6-dichloro-pyrimidin-2-yl)-amide	
278	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	383
	carboxylic acid (3-fluoro-phenyl)-amide	
279	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	410
2/3	carboxylic acid (3-nitro-phenyl)-amide	
	5,6-Dichloro-3-{[1-(4-chloro-phenyl)-5-trifluoromethyl-	
280	1H-pyrazole-4-carbonyl]-amino}-pyrazine-2-carboxylic	493
	acid methyl ester	

281	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	385
	carboxylic acid (2-cyclopentyl-ethyl)-amide	
282	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid	243
	benzylamide	
283	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid tert-	209
	butylamide	203
284	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid phenethyl-	257
20.	amide	20 /
285	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid	249
203	cyclohexylmethyl-amide	249
286	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid	221
200	cyclopentylamide	221
287 .	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid (biphenyl-	319
207 .	3-ylmethyl)-amide	317
288	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-	379
200	trifluoromethyl-benzylamide	317
289	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3-	311
207	trifluoromethyl-benzylamide	511
290	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid	287
250	(benzo[1,3]dioxol-5-ylmethyl)-amide	207
291	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3,4-	311
271	dichloro-benzylamide	311
292	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	327
272	pyrrolidin-1-yl-methanone	321
293	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	410
2)3	(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone	410
294	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	419
2)4	(4-pyridin-2-yl-piperazin-1-yl)-methanone	415
	(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-[1-(4-	
295	fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	476
	methanone	
296	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
290	carboxylic acid 4-methoxy-benzylamide	393

297	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	423
	carboxylic acid [2-(4-methoxy-phenoxy)-ethyl]-amide	
298	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	449
290	carboxylic acid 3-fluoro-5-trifluoromethyl-benzylamide	, 12
299	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	356
299	(4-methyl-piperazin-1-yl)-methanone	330
	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
300	carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-	403
	amide	
	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
301	carboxylic acid [cyclopropyl-(4-methoxy-phenyl)-	433
-	methyl]-amide	
	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
302	carboxylic acid (2,3-dihydro-benzo[d]imidazo[2,1-	447
	b]thiazol-6-yl)-amide	
202	2-{[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	511
303	carbonyl]-amino}-3-phenyl-propionic acid benzyl ester	311
204	4-{[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	421
304	carbonyl]-amino}-benzoic acid ethyl ester	721
205	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
305	carboxylic acid (3-methanesulfonyl-phenyl)-amide	721
•	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
306	carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-	413
	amide	
307	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	369
307	carboxylic acid (thiophen-2-ylmethyl)-amide	
200	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	353
308	carboxylic acid (furan-2-ylmethyl)-amide	
200	1-[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	384
309	carbonyl]-piperidine-3-carboxylic acid amide	504
210	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	389
310	carboxylic acid (2-phenyl-cyclopropyl)-amide	300

311	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	357
311	(3-hydroxy-piperidin-1-yl)-methanone	201
312	4-Phenyl-1-(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-	398
312	piperidine-4-carbonitrile	396
212	1-(5-tert-Butyl-2-methyl-2H-pyrazole-3-carbonyl)-4-	350
313	phenyl-piperidine-4-carbonitrile	330
314	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	457
314	carboxylic acid (3-methanesulfonyl-phenyl)-methyl-amide	437
215	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	461
315	carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	401
216	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	202
316	carboxylic acid methylamide	303
217	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	217
317	carboxylic acid dimethylamide	317
210	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	407
318	carboxylic acid (3-acetyl-phenyl)-amide	407
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
319	carboxylic acid (5-ethanesulfonyl-2-methoxy-phenyl)-	487
	amide	
220	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	443
320	carboxylic acid (4-methanesulfonyl-phenyl)-amide	440
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
321	carboxylic acid (1,1-dioxo-1H-1lambda*6*-	453
,	benzo[b]thiophen-6-yl)-amide	
322	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
322	carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	711
323	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
323	carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	711
. 224	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
324	carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	721
225	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
. 325	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	72/
L	<u> </u>	

326	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	461
327	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
328	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
329	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	323
330	(5-Chloro-1-methyl-1H-pyrazol-4-yl)-(4-methyl-piperazin-1-yl)-methanone	242
331	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1- methyl-hexyl)-amide	257
332	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	243
333	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2- pyridin-2-yl-ethyl)-amide	264
334	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	427
335	[1-(4-Chloro-phenyl)-5-propyl-1H-pyrazol-4-yl]-(4-methyl-piperazin-1-yl)-methanone	346
336	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-methyl-hexyl)-amide	361
337	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	347
338	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	368
339	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid ethyl- pyridin-4-ylmethyl-amide	278
340	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid benzyl- isopropyl-amide	291
341	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	332

242	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-	272
342	diethylamino-propyl)-amide	
242	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 2,4-	309
343	dimethoxy-benzylamide	309
344	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	382
344	acid ethyl-pyridin-4-ylmethyl-amide	302
345	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	395
343	acid benzyl-isopropyl-amide	373
346	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	436
. 340	acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	150
347	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	376
347	acid (3-diethylamino-propyl)-amide	370
348	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	413
340	acid 2,4-dimethoxy-benzylamide	415
349	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid benzyl-	263
349	methyl-amide	203
350	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3,4-	271
330	difluoro-phenyl)-amide	2,1
351	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-	303
. 331	trifluoromethyl-phenyl)-amide	303
352	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid methyl-	250
332	pyridin-2-yl-amide	
353	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-	277
555	phenyl-propyl)-amide	
354	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	367
334	acid benzyl-methyl-amide	
355	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	375
333	acid (3,4-difluoro-phenyl)-amide	
356	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	407
330	acid (3-trifluoromethyl-phenyl)-amide	
357	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	354
551	acid methyl-pyridin-2-yl-amide	

358	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	381
	acid (3-phenyl-propyl)-amide	
359	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	264
	pyridin-4-yl-ethyl)-amide	
360	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid	293
300	(benzo[1,3]dioxol-5-ylmethyl)-amide	
361	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid	263
301	phenethyl-amide	
362	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	253
. 302	ethyl-2H-pyrazol-3-yl)-amide	200
363	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3,4-	331
303	dichloro-phenyl)-ethyl]-amide	331
364	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	368
304	acid (2-pyridin-4-yl-ethyl)-amide	500
265	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	397
365	acid (benzo[1,3]dioxol-5-ylmethyl)-amide	35,
266	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	367
366	acid phenethyl-amide	307
267	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	357
367	acid (2-ethyl-2H-pyrazol-3-yl)-amide	33,
269	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	435
368	acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	1 433
260	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3-	331
369	trifluoromethyl-phenyl)-ethyl]-amide	
270	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	269
370	thiophen-2-yl-ethyl)-amide	269
271	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(4-	297
371	chloro-phenyl)-ethyl]-amide	291
272	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 3-	317
372	trifluoromethyl-benzylamide	J11
272	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-	313
373	methanesulfonyl-phenyl)-amide	313

374	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	435
375	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	373
376	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	401
377	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	421
378	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	417
379	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	302
380	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	281
381	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	281
382	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1- ethyl-pyrrolidin-2-ylmethyl)-amide	270
383	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1- ethyl-pyrrolidin-2-ylmethyl)-amide	270
384	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	406
385	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	385
386	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	385
387	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	374
388	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	374
389	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 2,6- dimethoxy-benzylamide	309

dimethoxy-phenyl)-ethyl]-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (5- chloro-pyridin-2-yl)-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	7/
391 dimethoxy-phenyl)-ethyl]-amide 323 392 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 393 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-27)	
dimethoxy-phenyl)-ethyl]-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (5- chloro-pyridin-2-yl)-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2- 277	323
chloro-pyridin-2-yl)-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	
chloro-pyridin-2-yl)-amide 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-	270
393 277	
	277
394 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 413	2
acid 2,6-dimethoxy-benzylamide	.5
395 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 401	\1
acid [2-(3-chloro-phenyl)-ethyl]-amide	'1
396 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 427	7
acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	. /
397 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 374	14
acid (5-chloro-pyridin-2-yl)-amide	374
398 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 381	201
acid (2-phenyl-propyl)-amide	'1
5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(4-	281
fluoro-phenyl)-ethyl]-amide	
5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(2,4-	.1
dichloro-phenyl)-ethyl]-amide	331
5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 325	325
(biphenyl-3-ylmethyl)-amide	
5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 236	236
pyridin-4-ylamide	
5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-	375
benzenesulfonyl-phenyl)-amide	
1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 385	5
acid [2-(4-fluoro-phenyl)-ethyl]-amide	,
1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 435	435
acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	

406	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	429
406	acid (biphenyl-3-ylmethyl)-amide	429
407	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	340
	acid pyridin-4-ylamide	540
400	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	479
408	acid (3-benzenesulfonyl-phenyl)-amide	4/2
400	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	425
409	carboxylic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide	423
410	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	381
410	carboxylic acid (3-hydroxy-phenyl)-amide	361
411	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
411	carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	411
	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-	
412	pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-	495
	ethyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
413	carboxylic acid (2-fluoro-5-methanesulfonyl-phenyl)-	461
<u> </u>	amide	
414	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
414	carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	727
415	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	409
415	carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]-amide	402
416	1-(3-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	447
410	carboxylic acid 3-trifluoromethyl-benzylamide	177
417	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	454
417	carboxylic acid (3-methanesulfonyl-phenyl)-amide	454
410	1-(4-Amino-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	424
418	carboxylic acid (3-methanesulfonyl-phenyl)-amide	727
419	1-(2,5-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid	393
417	[2-(3-chloro-phenyl)-ethyl]-amide	
420	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	438
420	carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	750
		

421	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	450
422	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	438
423	1-(4-Amino-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	408
424	1-(4-Guanidino-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-methanesulfonyl-phenyl)-amide	466
425	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	393
426	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	393
427	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	393
428	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	427
429	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	427
430	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	427
431	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	377
432	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	377
433	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	377
434	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	427
435	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-ethyl-phenyl)-ethyl]-amide	387
436	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	419

437	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	419
438	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	365
439	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	363
440	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	379
441	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	379
442	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-methyl-benzylamide	359
443	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-methyl-benzylamide	359
444	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	413
445	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-fluoro-5-trifluoromethyl-benzylamide	431
446	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-hydroxy-phenyl)-ethyl]-amide	409
447	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-hydroxy-phenyl)-ethyl]-amide	375
448	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	375
449	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	359
450	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2- (2,6-dichloro-phenyl)-ethyl]-amide	393
451	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	375
452	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	359

453	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-	393
455	(2,6-dichloro-phenyl)-ethyl]-amide	<i>J</i> /J
454	1-Benzyl-1H-pyrazole-4-carboxylic acid (3-	355
	methanesulfonyl-phenyl)-amide	300
455	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-	339
433	phenyl)-ethyl]-amide	
456	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-	373
450	phenyl)-ethyl]-amide	
457	1-p-Tolyl-1H-pyrazole-4-carboxylic acid (3-	355
457	methanesulfonyl-phenyl)-amide	
458	1-p-Tolyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-	339
100	phenyl)-ethyl]-amide	,
459	1-p-Tolyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-	373
	phenyl)-ethyl]-amide	
460	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3-	375
	methanesulfonyl-phenyl)-amide	
461	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-	359
	chloro-phenyl)-ethyl]-amide	
462	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-	393
	(2,6-dichloro-phenyl)-ethyl]-amide	,
463	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid	409
	(3-methanesulfonyl-phenyl)-amide	
464	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid	393
	[2-(3-chloro-phenyl)-ethyl]-amide	
465	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid	427
	[2-(2,6-dichloro-phenyl)-ethyl]-amide	
466	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid (3-	419
	methanesulfonyl-phenyl)-amide	
467	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-	403
	chloro-phenyl)-ethyl]-amide	
468	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid [2-	437
	(2,6-dichloro-phenyl)-ethyl]-amide	

460	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid (3-	359
469	methanesulfonyl-phenyl)-amide	339
470	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-	343
	chloro-phenyl)-ethyl]-amide	J+J
471	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid [2-	377
4/1	(2,6-dichloro-phenyl)-ethyl]-amide	377
472	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid (3-	371
412	methanesulfonyl-phenyl)-amide	371
473	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid [2-	355
4/3	(3-chloro-phenyl)-ethyl]-amide	333
474	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid [2-	389
474	(2,6-dichloro-phenyl)-ethyl]-amide	307
475	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	391
475	[2-(3,4-dihydroxy-phenyl)-ethyl]-amide	321
176	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	375
476	[2-(4-hydroxy-phenyl)-ethyl]-amide	373
477	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	363
4//	carboxylic acid benzylamide	303
478	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	377
4/0	carboxylic acid phenethyl-amide	3,,
479	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
479	carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	111
480	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
400	carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	
481	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	411
701	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	
482	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	445
702	carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	177
483	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	445
705	carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	
484	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	445
484	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	

485	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
.05	carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	
486	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
400	carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	
487	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
407	carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	
	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
488	carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-	445
	amide	
489	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	433
409	carboxylic acid (2-trifluoromethyl-phenyl)-amide	155
490	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	401
490	carboxylic acid (2,4-difluoro-phenyl)-amide	401
401	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	407
491	carboxylic acid (4-isopropyl-phenyl)-amide	707
400	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	451
492	carboxylic acid (2-fluoro-5-trifluoromethyl-phenyl)-amide	451
493	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	405
493	carboxylic acid (2-isopropenyl-phenyl)-amide	105
404	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
494	carboxylic acid (4-ethyl-phenyl)-amide	373
495	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	451
433	carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide	,,,,
496	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	449
	carboxylic acid (2-trifluoromethoxy-phenyl)-amide	
497	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
431	carboxylic acid (2,5-dimethyl-phenyl)-amide	_
498	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
1 70	carboxylic acid (2,3,4-trifluoro-phenyl)-amide	
499	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	383
1 77	carboxylic acid (2-fluoro-phenyl)-amide	
500	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	421
500	carboxylic acid (4-tert-butyl-phenyl)-amide	121

501	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-5-trifluoromethyl-phenyl)-amide	467
502	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-trifluoromethyl-phenyl)-amide	433
503	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid o-tolylamide	379
504	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,4-dimethyl-phenyl)-amide	393
505	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-tert-butyl-phenyl)-amide	421
506	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,6-dimethyl-phenyl)-amide	393
507	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-ethoxy-phenyl)-amide	409
508	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-chloro-pyridin-3-yl)-amide	400
509	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,4-dichloro-phenyl)-amide	433
510	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid biphenyl-4-ylamide	441
511	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (5-chloro-2-methyl-phenyl)-amide	413
512	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-chloro-phenyl)-amide	399
513	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-cyano-phenyl)-amide	390
514	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-benzenesulfonyl-phenyl)-amide	
515	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-methoxy-biphenyl-3-yl)-amide	471
516	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-morpholin-4-yl-phenyl)-amide	450

517	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	433
	carboxylic acid (4-trifluoromethyl-phenyl)-amide	
518	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	450
	carboxylic acid [4-(ethyl-isopropyl-amino)-phenyl]-amide	
519	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	413
317	carboxylic acid (2-chloro-5-methyl-phenyl)-amide	
520	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	448
320	carboxylic acid (2-piperidin-1-yl-phenyl)-amide	
521	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	408
321	carboxylic acid (4-dimethylamino-phenyl)-amide	
500	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	409
522	carboxylic acid (5-methoxy-2-methyl-phenyl)-amide	402
502	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	447
523	carboxylic acid (4-methyl-2-oxo-2H-chromen-7-yl)-amide	/
504	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	429
524	carboxylic acid (2-chloro-5-methoxy-phenyl)-amide	120
525	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	416
323	carboxylic acid quinolin-8-ylamide	,10
526	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	430
320	carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	
527	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	480
327	carboxylic acid [2-(1H-indol-2-yl)-phenyl]-amide	
528	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	404
328	carboxylic acid (3-cyanomethyl-phenyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
529	carboxylic acid [5-chloro-2-(4-chloro-phenylsulfanyl)-	541
	phenyl]-amide	
530	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	390
	carboxylic acid (2-cyano-phenyl)-amide	
531	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	409
751	carboxylic acid (4-methoxy-phenyl)-methyl-amide	
532	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
752	carboxylic acid (4-methoxy-phenyl)-amide	

522	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	42.4
533	carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide	434
534	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	467
<i>33</i> 4	carboxylic acid (2-chloro-4-trifluoromethyl-phenyl)-amide	407
525	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	397
535	carboxylic acid (5-fluoro-2-methyl-phenyl)-amide	391
536	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	386
330	carboxylic acid (3-methyl-isothiazol-5-yl)-amide	360
537	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	372
337	carboxylic acid thiazol-2-ylamide	312
538	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	432
336	carboxylic acid (5-phenyl-oxazol-2-yl)-amide	732
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
539	carboxylic acid (1,1-dioxo-tetrahydro-1lambda*6*-	407
	thiophen-3-yl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
540	carboxylic acid (5-methylsulfanyl-1H-[1,2,4]triazol-3-yl)-	402
	amide	
541	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	356
341	carboxylic acid (1H-[1,2,4]triazol-3-yl)-amide	330
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
542	carboxylic acid (5-trifluoromethyl-[1,3,4]thiadiazol-2-yl)-	441
-	amide	
543	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	370
343	carboxylic acid (3-methyl-isoxazol-5-yl)-amide	370
544	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	448
344	carboxylic acid (4-phenyl-thiazol-2-yl)-amide	140
545	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	422
545	carboxylic acid benzothiazol-2-ylamide	
546	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	405
J-10	carboxylic acid (1H-benzoimidazol-2-yl)-amide	
547	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	393
347	carboxylic acid 3-methoxy-benzylamide	

548	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2-methoxy-benzylamide	393
549	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-methyl-benzylamide	377
550	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	377
551	carboxylic acid 4-methyl-benzylamide 1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	397
552	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	431
553	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	423
554	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2,3-dimethoxy-benzylamide	423
555	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 4-chloro-benzylamide	397
556	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid cyclohexylmethyl-amide	369
557	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2,4-dichloro-benzylamide	431
558	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-iodo-benzylamide	489
. 559	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2-fluoro-benzylamide	381
560	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 4-trifluoromethyl-benzylamide	431
561	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	357
562	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	407
563	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide	449

564	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	431
565	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	499
566	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 2,6-dimethoxy-benzylamide	423
567	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3,5-dimethoxy-benzylamide	423
568	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-phenyl-ethyl)-amide	377
569	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (pyridin-2-ylmethyl)-amide	364
570	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	455
571	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	407
572	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	437
573	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	437
574	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-o-tolyl-ethyl)-amide	391
575	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	405
576	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	405
577	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-phenyl-butyl)-amide	405
578	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]-amide	393
579	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-chloro-phenyl)-amide	383

580	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	363
360	carboxylic acid o-tolylamide	303
581	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	363
301	carboxylic acid m-tolylamide	303
582	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	379
362	carboxylic acid (2-methoxy-phenyl)-amide	319
583	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	367
203	carboxylic acid (3-fluoro-phenyl)-amide	307
584	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	385
304	carboxylic acid (2,4-difluoro-phenyl)-amide	363
585	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	449
303	carboxylic acid (3-trifluoromethoxy-phenyl)-amide	443
586	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	399
360	(2-trifluoromethyl-phenyl)-amide	399
587	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	407
367	acid (2-trifluoromethyl-phenyl)-amide	407
588	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	373
366	trifluoromethyl-phenyl)-amide	373
589	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	366
369	(2-chloro-pyridin-3-yl)-amide	
590	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	374
390	acid (2-chloro-pyridin-3-yl)-amide	3/4
591	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	340
331	chloro-pyridin-3-yl)-amide	340
592	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	373
372	(4-isopropyl-phenyl)-amide	373
593	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	381
	acid (4-isopropyl-phenyl)-amide	301
594	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-	347
J)7	isopropyl-phenyl)-amide	J-71
595	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	365
<i></i>	(4-chloro-phenyl)-amide	505

acid (4-chloro-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 359. 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 367. 368. 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 369. 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 360. 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 360. 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 360. 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide
chloro-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 359. 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 367. 368. 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 369. 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide
chloro-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 359 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 367 600 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 601 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 366 607 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 608 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 609 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide
1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-cyano-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide
(4-ethyl-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide
367 acid (4-ethyl-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 333 acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 356 acid (4-cyano-phenyl)-amide 367 367 368 369 369 360 360 360 360 360 360 360 360 360 360
acid (4-ethyl-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 356 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide
600 ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 356 602 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 364 603 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 604 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 415
ethyl-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 356 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 364 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
601 (4-cyano-phenyl)-amide 356 602 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 364 603 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 330 cyano-phenyl)-amide 415 604 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 415 605 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
(4-cyano-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide
acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 330 cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
acid (4-cyano-phenyl)-amide 1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide 330 cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
603 cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
cyano-phenyl)-amide 1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
604 (2-trifluoromethoxy-phenyl)-amide 415 605 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
(2-trifluoromethoxy-phenyl)-amide 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 423
605 423
acid (2-trifluoromethoxy-phenyl)-amide
1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-
trifluoromethoxy-phenyl)-amide
1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 416
(4-morpholin-4-yl-phenyl)-amide
1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 424
acid (4-morpholin-4-yl-phenyl)-amide
1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-
morpholin-4-yl-phenyl)-amide
1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 349
(2-fluoro-phenyl)-amide
611 1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic 357
acid (2-fluoro-phenyl)-amide

•	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	
612	fluoro-phenyl)-amide	323
	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	
613	(4-trifluoromethyl-phenyl)-amide	399
 	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	
614	acid (4-trifluoromethyl-phenyl)-amide	407
	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-	
615	trifluoromethyl-phenyl)-amide	373
	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	
616	(3-trifluoromethyl-phenyl)-amide	399
	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-	272
617	trifluoromethyl-phenyl)-amide	373
	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	414
618	(2-piperidin-1-yl-phenyl)-amide	414
<u></u>	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	422
619	acid (2-piperidin-1-yl-phenyl)-amide	422
620	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-	388
	piperidin-1-yl-phenyl)-amide	500
621	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	345
021	o-tolylamide	J , 0
622	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	353
	acid o-tolylamide	
623	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid o-	319
023	tolylamide	
624	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	382
021	quinolin-8-ylamide	
625	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	390
020	acid quinolin-8-ylamide	
626	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid	356
	quinolin-8-ylamide	
627	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	375
<i>521</i>	(4-ethoxy-phenyl)-amide	

628	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethoxy-phenyl)-amide	383
629	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-	349
027	ethoxy-phenyl)-amide	
630	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	437
	[2-(4-bromo-phenyl)-ethyl]-amide	
631	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	445
031	acid [2-(4-bromo-phenyl)-ethyl]-amide	
632	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-	411
032	bromo-phenyl)-ethyl]-amide	
633	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	387
033	[2-(3,4-dimethyl-phenyl)-ethyl]-amide	
634	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	395
054	acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	
635	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-	361
	dimethyl-phenyl)-ethyl]-amide	
636	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-	367
030	chloro-phenyl)-ethyl]-amide	
637	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	389
037	[2-(2-methoxy-phenyl)-ethyl]-amide	
638	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	397
038	acid [2-(2-methoxy-phenyl)-ethyl]-amide	
639	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2-	363
039	methoxy-phenyl)-ethyl]-amide	
640	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-	351
040	fluoro-phenyl)-ethyl]-amide	
641	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-	401
041	dichloro-phenyl)-ethyl]-amide	
642	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-	367
U 4 ∠	chloro-phenyl)-ethyl]-amide	
643	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	435
043	acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	

644	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,6-	401
011	dichloro-phenyl)-ethyl]-amide	
645	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	389
043	[2-(3-methoxy-phenyl)-ethyl]-amide	
646	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	397
040	acid [2-(3-methoxy-phenyl)-ethyl]-amide	
647	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-	363
047	methoxy-phenyl)-ethyl]-amide	
648	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	373
046	(2-o-tolyl-ethyl)-amide	3,3
649	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	381
049	acid (2-o-tolyl-ethyl)-amide	501
650	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-o-	347
	tolyl-ethyl)-amide	3.7
	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	375
651	(2-phenoxy-ethyl)-amide	373
652	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	383
032	acid (2-phenoxy-ethyl)-amide	303
653	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	387
. 033	(4-phenyl-butyl)-amide	307
654	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	395
034	acid (4-phenyl-butyl)-amide	
655	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-	361
633	phenyl-butyl)-amide	301
656	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	385
656	(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	303
657	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic	393
657	acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	373
650	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid	359
658	(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	337
(50	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid	387
659	[2-(2,4-dimethyl-phenyl)-ethyl]-amide	367

660	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	395
661	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	361
662	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid findan-1-ylamide	371
663	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid indan-1-ylamide	379
664	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	471
665	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	423
666	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-o-tolyl-ethyl)-amide	407
667	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-phenyl-butyl)-amide	421
668	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	421
669	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	421
670	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	423
671	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)- amide	419
672	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,4,6-triethyl-phenyl)-amide	449
673	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-ethyl-6-methyl-phenyl)-amide	407
674	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,4,6-trimethyl-phenyl)-amide	407
675	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,6-diethyl-phenyl)-amide	421

	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	_
676	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2,5-bis-trifluoromethyl-phenyl)-amide	501
677	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	449
011	carboxylic acid (2,6-diisopropyl-phenyl)-amide	
(70	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	421
678	carboxylic acid (2-isopropyl-6-methyl-phenyl)-amide	
(50	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	494
679	carboxylic acid (2,4,6-triethyl-3-nitro-phenyl)-amide	727
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	401
680	carboxylic acid (3,4-difluoro-phenyl)-amide	401
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	477
681	carboxylic acid (2,5-di-tert-butyl-phenyl)-amide	4//
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	455
682	carboxylic acid (3-chloro-2,6-diethyl-phenyl)-amide	433
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	447
683	carboxylic acid (4-cyclohexyl-phenyl)-amide	44/
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	521
684	carboxylic acid (2,5-dibromo-phenyl)-amide	321
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	407
685	carboxylic acid (2-isopropyl-phenyl)-amide	407
606	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4-	325
686	chloro-benzylamide	323
	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 2-	325
687	chloro-benzylamide	323
	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 2-	309
688	fluoro-benzylamide	303
	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4-	309
689	fluoro-benzylamide	309
	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-	311
690	chloro-phenyl)-amide	
	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (3-	311
691	chloro-phenyl)-amide	

692	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-	311
072	chloro-phenyl)-amide	211
693	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	321
073	carboxylic acid benzylamide	3 2 1
694	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	335
054	carboxylic acid phenethyl-amide	555
695	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	365
0,7,3	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	303
696	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	355
	carboxylic acid 4-chloro-benzylamide	333
697	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	355
097	carboxylic acid 2-chloro-benzylamide	333
698	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	339
096	carboxylic acid 2-fluoro-benzylamide	339
699	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	339
099	carboxylic acid 4-fluoro-benzylamide	339
700	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	341
700	carboxylic acid (2-chloro-phenyl)-amide	341
701	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	341
701	carboxylic acid (3-chloro-phenyl)-amide	341
702	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	341
702	carboxylic acid (4-chloro-phenyl)-amide	341
703	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	277
705	phenylamide	
704	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	292
704	(pyridin-3-ylmethyl)-amide	2,2
705	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	307
. 703	carboxylic acid phenylamide	
706	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	322
,,,,	carboxylic acid (pyridin-3-ylmethyl)-amide	
707	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	309
707	acid benzylamide	305

708	1-Benzyl-1H-pyrazole-4-carboxylic acid benzylamide	291
709	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	341
705	acid [2-(2-fluoro-phenyl)-ethyl]-amide	541
710	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-	323
710	phenyl)-ethyl]-amide	323
711	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-	323
/11	phenyl)-ethyl]-amide	323
712	1-Benzyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	305
713	1-Benzyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	341
714	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-	323
/14	phenyl)-ethyl]-amide	323
715	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	353
713	acid (benzo[1,3]dioxol-5-ylmethyl)-amide	333
716	1-Benzyl-1H-pyrazole-4-carboxylic acid	335
710	(benzo[1,3]dioxol-5-ylmethyl)-amide	333
717	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	341
717	acid [2-(4-fluoro-phenyl)-ethyl]-amide] 3,1
718	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-	323
710	phenyl)-ethyl]-amide	323
719	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	343
715	acid 4-chloro-benzylamide	3.3
720	1-Benzyl-1H-pyrazole-4-carboxylic acid 4-chloro-	325
	benzylamide	
721	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	357
	acid [2-(3-chloro-phenyl)-ethyl]-amide	
722	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	343
. 	acid 2-chloro-benzylamide	
723	1-Benzyl-1H-pyrazole-4-carboxylic acid 2-chloro-	325
	benzylamide	
724	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	357
	acid [2-(4-chloro-phenyl)-ethyl]-amide	
725	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-	339
	phenyl)-ethyl]-amide	

726	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	327
720	acid 2-fluoro-benzylamide	327
727	1-Benzyl-1H-pyrazole-4-carboxylic acid 2-fluoro-	309
121	benzylamide	20)
728	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	353
720	acid [2-(2-methoxy-phenyl)-ethyl]-amide	555
729	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-	335
123	phenyl)-ethyl]-amide	333
730	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	327
730	acid 4-fluoro-benzylamide	327
731	1-Benzyl-1H-pyrazole-4-carboxylic acid 4-fluoro-	309
/31	benzylamide	309
722	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	353
732	acid [2-(3-methoxy-phenyl)-ethyl]-amide	333
722	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-	335
733	phenyl)-ethyl]-amide	333
724	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	310
734	acid (pyridin-3-ylmethyl)-amide	310
725	1-Benzyl-1H-pyrazole-4-carboxylic acid (pyridin-3-	292
735 .	ylmethyl)-amide	292
726	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	391
736	acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	391
727	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-	373
737	trifluoromethyl-phenyl)-ethyl]-amide	3/3
720	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	395
738	yl]-3-methoxy-benzamide	393
720	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	443
739	yl]-3-methanesulfonyl-benzamide	443
740	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (3-	355 .
740	methanesulfonyl-phenyl)-amide	333 .
7.41	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	385
741	carboxylic acid (3-methanesulfonyl-phenyl)-amide	303

740	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic	373
742	acid (3-methanesulfonyl-phenyl)-amide	3/3
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
743	carboxylic acid (5,6-dimethyl-1H-benzoimidazol-2-yl)-	433
	amide	
744	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
744	carboxylic acid (1-methyl-1H-benzoimidazol-2-yl)-amide	412
745	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	419
745	carboxylic acid (1H-benzoimidazol-2-yl)-methyl-amide	415
746	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-tert-	333
746	butyl-phenyl)-amide	333
747	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-	373
747	(2,4-dichloro-phenyl)-ethyl]-amide	373
748	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-	333
. 748	phenyl-butyl)-amide	333
749	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-	333
149	(2,4-dimethyl-phenyl)-ethyl]-amide	
750	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(2-	339
750	chloro-phenyl)-ethyl]-amide	
751	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-	319
731	isopropyl-phenyl)-amide	
752	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-o-	319
, 132	tolyl-ethyl)-amide	
753	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(4-	339
755	chloro-phenyl)-ethyl]-amide	
754	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	403
754	carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	
755	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	363
,	carboxylic acid (4-phenyl-butyl)-amide	
756	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	363
750	carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	
757	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	369
131	carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	

758	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4- carboxylic acid (4-isopropyl-phenyl)-amide	349
759	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	349
	carboxylic acid (2-o-tolyl-ethyl)-amide	
760	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	369
	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	
761	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-	342
701	pyrrol-1-yl-phenyl)-amide	0
762	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-	361
702	trifluoromethoxy-phenyl)-amide	501
763	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid	328
703	quinolin-8-ylamide	320
764	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	363
764	carboxylic acid (4-tert-butyl-phenyl)-amide	303
765	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	372
703	carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	312
766	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	391
700	carboxylic acid (2-trifluoromethoxy-phenyl)-amide	371
767	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-	358
707	carboxylic acid quinolin-8-ylamide	330
768	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-	311
708	benzamide	JII
769	N-(2-Methyl-5-thiophen-2-yl-2H-pyrazol-3-yl)-benzamide	283
770	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-benzamide	241
771	N-(2-Methyl-5-phenyl-2H-pyrazol-3-yl)-benzamide	277
770	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	365
772	yl]-benzamide	303
772	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-3-	220
773	fluoro-benzamide	329
774	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-3-fluoro-	259
774	benzamide	233
775	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	383
		1 202

776	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-2- methoxy-benzamide	341
777	2-Methoxy-N-(2-methyl-5-thiophen-2-yl-2H-pyrazol-3-yl)-benzamide	313
778	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-2-methoxy- benzamide	271
779	2-Methoxy-N-(2-methyl-5-phenyl-2H-pyrazol-3-yl)- benzamide	307
780	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-2-methoxy-benzamide	395
781	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-3- methanesulfonyl-benzamide	389
782	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-3- methanesulfonyl-benzamide	319
783	3-Methanesulfonyl-N-(2-methyl-5-phenyl-2H-pyrazol-3-yl)-benzamide	355
784	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea	458
785	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- carbamic acid 2-methoxy-phenyl ester	411
786	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-methyl-5-trifluoromethyl-1H- benzoimidazol-2-yl)-amide	487
787	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (5-fluoro-1-methyl-1H-benzoimidazol-2- yl)-amide	437
788	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,6-dimethyl-1H-benzoimidazol-2-yl)-amide	433
789	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (5,6-dichloro-1-methyl-1H- benzoimidazol-2-yl)-amide	487

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
792	carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-methyl-	475
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
793	carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-methyl-	414
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
794	carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-methyl-amide	425
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
795	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-methyl-	475
	amide	,
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
796	carboxylic acid [2-(2-chloro-phenyl)-ethyl]-methyl-amide	441
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
797	carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-methyl-amide	425
· · · · · · · · · · · · · · · · · · ·	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
798	carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-methyl-amide	425
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
799	carboxylic acid [2-(3-chloro-phenyl)-ethyl]-methyl-amide	441
<u>' </u>	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	. <u>. </u>
800	carboxylic acid (5-ethanesulfonyl-2-methoxy-phenyl)-	501
	methyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	441
801	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-methyl-amide	441
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
802	carboxylic acid (2-fluoro-5-methanesulfonyl-phenyl)-	475
	methyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
803	carboxylic acid methyl-(3-trifluoromethoxy-phenyl)-	463
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
804	carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-methyl-	437
	amide	
L		L

	1	
805	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	483
	carboxylic acid benzyl-(1-phenyl-ethyl)-amide	
806	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	407
	carboxylic acid methyl-phenethyl-amide	
807	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	471
	carboxylic acid bis-pyridin-3-ylmethyl-amide	
808	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	471
	carboxylic acid bis-pyridin-2-ylmethyl-amide	
809	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	433
005	carboxylic acid (2-cyano-ethyl)-pyridin-3-ylmethyl-amide	.55
810	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	435
810	(4-pyridin-2-yl-piperazin-1-yl)-methanone	433
811	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	435
011	carboxylic acid isopropyl-phenethyl-amide	433
812	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	483
812	carboxylic acid benzyl-(1-phenyl-ethyl)-amide	403
012	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	408
813	carboxylic acid ethyl-pyridin-4-ylmethyl-amide	406
014	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	341
814	(2,5-dihydro-pyrrol-1-yl)-methanone	541
815	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	361
813	thiazolidin-3-yl-methanone	301
016	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	439
816	carboxylic acid ethyl-(5-nitro-pyridin-2-yl)-amide	439
017	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	416
817	carboxylic acid quinolin-6-ylamide	410
010	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	466
818	carboxylic acid (4-nitro-benzyl)-propyl-amide	400
010	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	116
819	[3-(4-methoxy-phenyl)-pyrazol-1-yl]-methanone	446
	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	426
820	(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone	426
L		L

1 51 (4 (011) 1 1) 5 4 10 11 1 477 14	
1	414
* * * * * * * * * * * * * * * * * * * *	
1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	432
yl]-3-(2,5-difluoro-phenyl)-thiourea	.52
1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	448
yl]-3-(3,4-dichloro-phenyl)-urea	440
1-[1-(4-Chloro-cyclohexa-2,4-dienyl)-5-trifluoromethyl-	464
1H-pyrazol-4-yl]-3-(4-trifluoromethyl-phenyl)-thiourea	404
1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	464
yl]-3-(2,4-dichloro-phenyl)-thiourea	464
[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	
carbamic acid 4-methoxy-phenyl ester	411
[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	201
carbamic acid phenyl ester	381
[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	261
carbamic acid isobutyl ester	361
1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	464
yl]-3-(2,6-diisopropyl-phenyl)-urea	464
[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	247
carbamic acid propyl ester	347
1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	410
carboxylic acid (3-methanesulfonyl-phenyl)-amide	410
5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-	400
pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	482
5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-	
pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-	446
amide	
5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-	
pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-	440
amide	
5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-	401
pyrazole-4-carboxylic acid pyridin-4-ylamide	401
	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3,4-dichloro-phenyl)-urea 1-[1-(4-Chloro-cyclohexa-2,4-dienyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(4-trifluoromethyl-phenyl)-thiourea 1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,4-dichloro-phenyl)-thiourea [1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid 4-methoxy-phenyl ester [1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid phenyl ester [1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid isobutyl ester 1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid propyl ester 1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid propyl ester 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide 5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide 5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-amide 5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-amide

	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-	
837	pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-	478
	amide	
020	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	448
838	4-carboxylic acid 4-trifluoromethyl-benzylamide	440
920	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	412
839	4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	712
840	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	406
840	4-carboxylic acid (1H-benzoimidazol-2-yl)-amide	400
841	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	367
041	4-carboxylic acid pyridin-4-ylamide	307
842	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	444
042	4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	
3 7	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-	
843	pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-	427
•	amide	
	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-	
844	pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-	389
	amide	
	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-	-
845	pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-	395
	amide	
846	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-	431
0-10	pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	
847	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	408
047	carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide	
848	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	394
040	carboxylic acid methyl-pyridin-3-ylmethyl-amide	
849	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	416
047	carboxylic acid quinolin-3-ylamide	
850	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	533
850	carboxylic acid benzyl-(3-methanesulfonyl-phenyl)-amide	555

0.51	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	471
851	carboxylic acid ethyl-(3-methanesulfonyl-phenyl)-amide	
	[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
852	carbonyl]-(3-methanesulfonyl-phenyl)-amino]-acetic acid	529
	ethyl ester	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
853	carboxylic acid cyanomethyl-(3-methanesulfonyl-phenyl)-	482
•	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
854	carboxylic acid (3-methanesulfonyl-phenyl)-naphthalen-2-	583
	ylmethyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
855	carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-3-	534
	ylmethyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
856	carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-2-	534
	ylmethyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
857	carboxylic acid (4-chloro-benzyl)-(3-methanesulfonyl-	567
	phenyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
858	carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-4-	534
	ylmethyl-amide	
859	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	483
639	carboxylic acid allyl-(3-methanesulfonyl-phenyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
860	carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl)-(3-	552
	methanesulfonyl-phenyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
861	carboxylic acid benzyl-[2-(2,6-dichloro-phenyl)-ethyl]-	551
	amide	

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
862	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-	601
	naphthalen-2-ylmethyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
863	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-3-	552
	ylmethyl-amide	
<u></u>	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
864	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-2-	552
	ylmethyl-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
865	carboxylic acid (4-chloro-benzyl)-[2-(2,6-dichloro-	585
	phenyl)-ethyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
866	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-4-	552
	ylmethyl-amide	
0.67	1-Benzyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-	394
867	pyrazol-4-yl]-urea	3,74
0.60	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	408
868	yl]-3-phenethyl-urea	400
0.60	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	426
869	yl]-3-[2-(4-fluoro-phenyl)-ethyl]-urea	120
070	Morpholine-4-carboxylic acid [1-(4-chloro-phenyl)-5-	374
870	trifluoromethyl-1H-pyrazol-4-yl]-amide	3/4
071	1-Butyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-	360
871	pyrazol-4-yl]-urea	300
972	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	422
872	yl]-3-(2-m-tolyl-ethyl)-urea	122
072	1-[2-(4-Chloro-phenyl)-ethyl]-3-[1-(4-chloro-phenyl)-5-	442
873	trifluoromethyl-1H-pyrazol-4-yl]-urea	
074	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	422
874	yl]-3-(3-phenyl-propyl)-urea	
075	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	372
875	yl]-3-cyclopentyl-urea	

876	1-Benzo[1,3]dioxol-5-ylmethyl-3-[1-(4-chloro-phenyl)-5-	438
0.0	trifluoromethyl-1H-pyrazol-4-yl]-urea	
877	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	409
	yl]-1-methyl-1-pyridin-3-ylmethyl-urea	
878	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	423
0,0	yl]-1-methyl-1-(2-pyridin-2-yl-ethyl)-urea	
879	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	414
0,5	carboxylic acid 3-trifluoromethyl-benzylamide	
880	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	378
,	carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	
881	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	372
001	carboxylic acid (1H-benzoimidazol-2-yl)-amide	
882	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	333
002	carboxylic acid pyridin-4-ylamide	
883	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	428
885	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	
884	1-(3-Chloro-phenyl)-3-[1-(4-chloro-phenyl)-5-	414
004	trifluoromethyl-1H-pyrazol-4-yl]-urea	
885	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	448
885	yl]-3-(4-trifluoromethyl-phenyl)-urea	
886	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	371
880	yl]-3-isoxazol-3-yl-urea	
887	1-(2-tert-Butyl-phenyl)-3-[1-(4-chloro-phenyl)-5-	436
	trifluoromethyl-1H-pyrazol-4-yl]-urea	
888	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	380
000	yl]-3-phenyl-urea	
889	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	445
669	yl]-3-(2-pyrrol-1-yl-phenyl)-urea	
	3-(2-Chloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid	
890	[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	480
	amide	
891	1,3-Bis-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-	548
071	pyrazol-4-yl]-urea	

892	4-Acetyl-[1,4]diazepane-1-carboxylic acid [1-(4-chloro-	429
092	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	123
893	1-Allyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-	344
093	pyrazol-4-yl]-urea Š	
894	1-(2-Amino-benzyl)-3-[1-(4-chloro-phenyl)-5-	409
	trifluoromethyl-1H-pyrazol-4-yl]-urea	.05
895	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	445
655	yl]-3-(4-diethylamino-1-methyl-butyl)-urea	
896	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	392
890	yl]-3-[2-(2-hydroxy-ethoxy)-ethyl]-urea	332
897	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	465
691	yl]-3-[2-(ethyl-m-tolyl-amino)-ethyl]-urea	105
898	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	415
636	yl]-3-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-urea	113
899	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	417
622	yl]-3-(2-morpholin-4-yl-ethyl)-urea	1,2,7
900	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	415
) 900	yl]-3-(2-piperidin-1-yl-ethyl)-urea	113
901	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	409
) 901	yl]-3-(2-pyridin-2-yl-ethyl)-urea	105
902	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	401
702	yl]-3-(2-pyrrolidin-1-yl-ethyl)-urea	
903	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	420
703	yl]-3-(1H-indazol-6-yl)-urea	,20
904	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	395
704	yl]-3-pyridin-3-ylmethyl-urea	
905	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	395
)03	yl]-3-pyridin-4-ylmethyl-urea	
906	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	424
) , , ,	yl]-3-(2-hydroxy-2-phenyl-ethyl)-urea	
907	1-[2-(4-Amino-phenyl)-ethyl]-3-[1-(4-chloro-phenyl)-5-	423
""	trifluoromethyl-1H-pyrazol-4-yl]-urea	

000	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	446
908	yl]-3-(5-phenyl-2H-pyrazol-3-yl)-urea	770
909	(3-{3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-	461
909	4-yl]-ureido}-propyl)-carbamic acid tert-butyl ester	401
910	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	412
910	yl]-3-(3-imidazol-1-yl-propyl)-urea	
911	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5-	463
<i>J</i> 11	trifluoromethyl-1H-pyrazol-4-yl]-urea	
912	4-Benzyl-piperazine-1-carboxylic acid [1-(4-chloro-	463
912	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	
913	4-(2-Chloro-phenyl)-piperazine-1-carboxylic acid [1-(4-	483
913	chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	.02
914	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	392
914	yl]-1,1-bis-(2-hydroxy-ethyl)-urea	372
915	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	403
913	yl]-3-(2-diethylamino-ethyl)-urea	.03
916	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	417
910	yl]-3-(3-diethylamino-propyl)-urea	
917	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	454
917	yl]-3-(2,3-dimethoxy-benzyl)-urea	
918	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	454
910	yl]-3-(2,4-dimethoxy-benzyl)-urea	
919	2,6-Dimethyl-morpholine-4-carboxylic acid [1-(4-chloro-	402
919	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	
920	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	486
920	yl]-1,1-bis-pyridin-2-ylmethyl-urea	
921	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	486
721	yl]-1,1-bis-pyridin-3-ylmethyl-urea	
922	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	376
344	yl]-1-ethyl-1-(2-hydroxy-ethyl)-urea	
923	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	423
743	yl]-1-ethyl-1-pyridin-4-ylmethyl-urea	

924	v4-(2-Hydroxy-ethyl)-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	417
025	4-Methyl-[1,4]diazepane-1-carboxylic acid [1-(4-chloro-	401
925	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	
926	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea	415
000	4-Methyl-piperazine-1-carboxylic acid [1-(4-chloro-	387
927	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	307
928	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-methylsulfanyl-ethyl)-urea	378
929	4-Pyrimidin-2-yl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	451
930	4-Benzo[1,3]dioxol-5-ylmethyl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	507
931	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-(2-cyano-ethyl)-1-pyridin-3-ylmethyl-urea	448
932	3-Hydroxy-pyrrolidine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	374
933	4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	441
934	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(tetrahydro-furan-2-ylmethyl)-urea	388
935	Thiazolidine-3-carboxylic acid [1-(4-chloro-phenyl)-5- trifluoromethyl-1H-pyrazol-4-yl]-amide	376
936	Thiomorpholine-4-carboxylic acid [1-(4-chloro-phenyl)-5- trifluoromethyl-1H-pyrazol-4-yl]-amide	390
937	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-thiophen-2-yl-ethyl)-urea	414
938	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-thiophen-2-ylmethyl-urea	400
939	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	430

940	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-	430
940	trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	150
941	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-	430
941	trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	450
942	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-	430
942	trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	.50
943	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-	414
7 4 3	trifluoromethyl-phenyl)-pyrrolidin-3-yl]-amide	
944	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-	414
7 44	trifluoromethyl-phenyl)-pyrrolidin-3-yl]-amide	
945	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	440
: 943	4-carboxylic acid 2,4-dimethoxy-benzylamide	440
946	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	424
940	4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	12-1
947	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	384
3 4 1	4-carboxylic acid (3-fluoro-phenyl)-amide	50.
948	[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazol-	406
94 0	4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-methanone	.00
949	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	396
949	4-carboxylic acid (3-methoxy-phenyl)-amide	
950	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	406
)30	4-carboxylic acid (2-isopropenyl-phenyl)-amide	
951	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	381
751	4-carboxylic acid (pyridin-3-ylmethyl)-amide	
952	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	462
752	4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	
953	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	451
	4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	
	[4-(2-Chloro-phenyl)-piperazin-1-yl]-[1-(6-chloro-	
954	pyridin-2-yl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	469
	methanone	
955	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	449
	4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	

055	(4-Benzyl-piperazin-1-yl)-[1-(6-chloro-pyridin-2-yl)-5-	449
956	trifluoromethyl-1H-pyrazol-4-yl]-methanone	442
067	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	407
957	carboxylic acid 2,4-dimethoxy-benzylamide	407
050	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	391
958	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	371
959	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	351
939	carboxylic acid (3-fluoro-phenyl)-amide	551
960	(3,4-Dihydro-2H-quinolin-1-yl)-(1-pyrimidin-2-yl-5-	373
900	trifluoromethyl-1H-pyrazol-4-yl)-methanone	3.3
961	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	363
901	carboxylic acid (3-methoxy-phenyl)-amide	303
062	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	373
962	carboxylic acid (2-isopropenyl-phenyl)-amide	373
062	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	348
963	carboxylic acid (pyridin-3-ylmethyl)-amide	340
964	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	429
904	carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	125
965	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	418
903	carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	
966	[4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyrimidin-2-yl-5-	436
900	trifluoromethyl-1H-pyrazol-4-yl)-methanone	
967	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	416
701	carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	
968	(4-Benzyl-piperazin-1-yl)-(1-pyrimidin-2-yl-5-	416
700	trifluoromethyl-1H-pyrazol-4-yl)-methanone	
969	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	489
707	pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
970	pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-	473
	ylmethyl)-amide	
971	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	433
7/1	pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	

972	(3,4-Dihydro-2H-quinolin-1-yl)-[1-(4-trifluoromethoxy-	455
	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	
973	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	445
913	pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	
974	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	455
<i>314</i>	pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	
975	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	430
913	pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
976	pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-	511
	ethyl]-amide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
977	pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-	500
	ethyl]-amide	
	[4-(2-Chloro-phenyl)-piperazin-1-yl]-[1-(4-	
978	trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazol-4-	518
	yl]-methanone	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
979	pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-	498
	amide	
000	(4-Benzyl-piperazin-1-yl)-[1-(4-trifluoromethoxy-phenyl)-	498
980	5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	, TJU
001	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	406
981	carboxylic acid 2,4-dimethoxy-benzylamide	700
000	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	390
982	carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	330
002	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	350
983	carboxylic acid (3-fluoro-phenyl)-amide	330
004	(3,4-Dihydro-2H-quinolin-1-yl)-(1-pyridin-2-yl-5-	372
984	trifluoromethyl-1H-pyrazol-4-yl)-methanone	312
000	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	362
985	carboxylic acid (3-methoxy-phenyl)-amide	302

carboxylic acid (2-isopropenyl-phenyl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (pyridin-3-ylmethyl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (2-(ethyl-m-tolyl-amino)-ethyl]-amide [4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide (4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-(1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	226	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	252
287 carboxylic acid (pyridin-3-ylmethyl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide [4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	986	carboxylic acid (2-isopropenyl-phenyl)-amide	372
carboxylic acid (pyridin-3-ylmethyl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide [4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide [4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone [4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone [5-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide [5-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide [6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-ethyl]-amide [6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide [7-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	007	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	2.47
1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-3-mide 415	987	carboxylic acid (pyridin-3-ylmethyl)-amide	341
carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide [4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	000	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	417
trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide (4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-([1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	988	carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	417
trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide (4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5- trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	000	[4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5-	135
carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide (4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	909	trifluoromethyl-1H-pyrazol-4-yl)-methanone	433
carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide (4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	000	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	415
trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 438 439 431 431 401 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	990	carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	415
trifluoromethyl-1H-pyrazol-4-yl)-methanone 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 438 439 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	001	(4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5-	115
450 4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 422 4-carboxylic acid (4-tert-butyl-phenyl)-amide 472 473 474 475 476 477 477 478 478 479 479 479 470 470 471 471 472 472 473 474 475 476 476 477 478 479 479 479 470 470 471 471 472 472 473 474 475 476 476 477 478 479 479 479 470 470 471 471 472 472 473 474 475 476 476 477 478 478 479 478 479 478 479 479 479 479 479 479 470 470 471 471 471 472 472 473 474 475 476 477 478 478 478 478 478 478 478 478 478	991	trifluoromethyl-1H-pyrazol-4-yl)-methanone	413
4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid {2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	002	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	450
4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	992	4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	430
4-carboxylic acid (4-tert-butyl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	002	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	422
4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	993	4-carboxylic acid (4-tert-butyl-phenyl)-amide	422
4-carboxylic acid bis-pyridin-2-ylmethyl-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	004	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	472
4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 401	994	4-carboxylic acid bis-pyridin-2-ylmethyl-amide	4/2
4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 401	005	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	428
4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-	993	4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	420
4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H- pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 401 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 417	006	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	412
997 4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 998 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-1001 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-1001	<i>)</i>	4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	712
4-carboxylic acid (4-fluoro-phenyl)-methyl-amide 4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1-(6-Chlor	997	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	308
pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 1001 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 417	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	4-carboxylic acid (4-fluoro-phenyl)-methyl-amide	370
pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 417	908	4-{[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-	438
431 4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 401 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 417	996	pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	730
4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 417	900	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	A31
1000 4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	999	4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	451
4-carboxylic acid (5-chloro-pyridin-2-yl)-amide 1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole- 1001 417	1000	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	401
1001 417	1000	4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	701
4-carboxylic acid isoquinolin-1-ylamide	1001	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-	417
	1001	4-carboxylic acid isoquinolin-1-ylamide	71/

1002	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	417
1002	carboxylic acid (2-trifluoromethoxy-phenyl)-amide	417
1003	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	389
1003	carboxylic acid (4-tert-butyl-phenyl)-amide	309
1004	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	439
1004	carboxylic acid bis-pyridin-2-ylmethyl-amide	433
1005	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	395
1003	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	373
1006	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	379
1000	carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	375
1007	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	365
1007	carboxylic acid (4-fluoro-phenyl)-methyl-amide	303
1008	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	411
1000	carboxylic acid (3-methanesulfonyl-phenyl)-amide	711
1009	4-[(1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	405
1005	carbonyl)-amino]-benzoic acid ethyl ester	405
1010	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	398
10,10	carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	370
1011	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	368
1011	carboxylic acid (5-chloro-pyridin-2-yl)-amide	300
1012	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	384
1012	carboxylic acid isoquinolin-1-ylamide	304
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1013	pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-	499
	amide	
1014	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	471
	pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	
1015	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	521
	pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	
:	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1016	pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-	477
	amide	

	1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
1017	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	461
	pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-	461
	amide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1018	pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-	447
	amide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	· · · · · · · · · · · · · · · · · · ·
1019	pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-	493
	amide	
	4-{[1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	407
1020	pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	487
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1021	pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	480
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1022	pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	450
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1023	pyrazole-4-carboxylic acid isoquinolin-1-ylamide	466
	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	
1024	carboxylic acid (2-trifluoromethoxy-phenyl)-amide	416
	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	
1025		388
	carboxylic acid (4-tert-butyl-phenyl)-amide	
1026	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	438
	carboxylic acid bis-pyridin-2-ylmethyl-amide	
1027	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	394
1021	carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	
1028	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	378
1028	carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	
1000	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	364
1029	carboxylic acid (4-fluoro-phenyl)-methyl-amide	307
	4-[(1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	404
1030	carbonyl)-amino]-benzoic acid ethyl ester	404
	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-	207
1031	carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	397

1032	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (5-chloro-pyridin-2-yl)-amide	367
1033	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid isoquinolin-1-ylamide	383
1034	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	450
1035	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	448
1036	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	448
1037	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5- trifluoromethyl-1H-pyrazol-4-yl]-urea	463
1038	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5- trifluoromethyl-1H-pyrazol-4-yl]-urea	463
1039	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-piperidin-4-yl)-amide	462
1040	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid piperidin-4-ylamide	372
1041	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-sulfamoyl-piperidin-4-yl)-amide	451
1042	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-dimethylsulfamoyl-piperidin-4-yl)- amide	479
1044	4-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole- 4-carbonyl]-amino}-piperidine-1-carboxylic acid ethyl ester	444
1045	{1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidin-4-yl}-carbamic acid tert-butyl ester	472
1046	(4-Amino-piperidin-1-yl)-[1-(4-chloro-phenyl)-5- trifluoromethyl-1H-pyrazol-4-yl]-methanone	372
1049	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-chloro-phenyl)-amide	399

1050	3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	437
	4-carbonyl]-amino}-benzoic acid ethyl ester	437
	3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	409
1052	4-carbonyl]-amino}-benzoic acid	407
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1053	carboxylic acid [3-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-	460
	amide	
1054	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	444
1054	carboxylic acid (3-sulfamoyl-phenyl)-amide	-1-1-1
1055	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	472
1055	carboxylic acid (3-dimethylsulfamoyl-phenyl)-amide	472
1056	(4-Benzylamino-piperidin-1-yl)-[1-(4-chloro-phenyl)-5-	462
1056	trifluoromethyl-1H-pyrazol-4-yl]-methanone	402
1057	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	480
1057	[4-(4-fluoro-benzylamino)-piperidin-1-yl]-methanone	400
1050	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	492
1058	[4-(4-methoxy-benzylamino)-piperidin-1-yl]-methanone	
1050	[4-(4-Chloro-benzylamino)-piperidin-1-yl]-[1-(4-chloro-	496
1059	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	450
1060	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	480
1000	carboxylic acid [1-(4-fluoro-benzyl)-piperidin-4-yl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1061	carboxylic acid [1-(3-chloro-benzyl)-piperidin-4-yl]-	496
	amide	
1062	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	480
1002	carboxylic acid [1-(2-fluoro-benzyl)-piperidin-4-yl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1063	carboxylic acid [1-(4-trifluoromethoxy-benzyl)-piperidin-	546
•	4-yl]-amide	
	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1064	carbonyl]-piperidine-2-carboxylic acid (3-	554
	methanesulfonyl-phenyl)-amide	

1065	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	373
1005	(4-hydroxy-piperidin-1-yl)-methanone	
	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	
1066	[2-(5-fluoro-1H-benzoimidazol-2-yl)-piperidin-1-yl]-	491
	methanone	
1067	[2-(1H-Benzoimidazol-2-yl)-piperidin-1-yl]-[1-(4-chloro-	473
1067	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	473
1060	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
1068	carboxylic acid (3-methanesulfonyl-phenyl)-amide	427
1060	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	445
1069	carboxylic acid (3-methanesulfonyl-phenyl)-amide	773
1070	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	377
1070	carboxylic acid phenethyl-amide	377
1071	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
1071	carboxylic acid phenethyl-amide	393
1070	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	377
1072	carboxylic acid benzyl-methyl-amide	3,,,
1072	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	395
1073	carboxylic acid benzyl-methyl-amide	373
1074	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	431
1074	carboxylic acid 3-trifluoromethyl-benzylamide	151
1075	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	449
1075	carboxylic acid 3-trifluoromethyl-benzylamide	
1076	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	504
	carbonyl]-piperidine-2-carboxylic acid phenethyl-amide	
	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1077	carbonyl]-piperidine-2-carboxylic acid benzyl-methyl-	504
1	amide	
	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1078	carbonyl]-piperidine-2-carboxylic acid 3-trifluoromethyl-	558
	benzylamide	
1079	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	446
10/9	carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	

1080	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	464
	carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	707
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1081	pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-	512
	methyl-amide	
	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1082	carboxylic acid (5-diisopropylamino-pyrimidin-2-yl)-	450
	amide	
	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1083	carboxylic acid (5-diisopropylamino-pyrimidin-2-yl)-	468
	amide	
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1084	pyrazole-4-carboxylic acid (5-diisopropylamino-	516
	pyrimidin-2-yl)-amide	
1005	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	428
1085	carboxylic acid (3-sulfamoyl-phenyl)-amide	420
1086	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	446
1080	carboxylic acid (3-sulfamoyl-phenyl)-amide	440
1087	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	494
1067	pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	424
1088	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	443
1000	carboxylic acid (2-chloro-pyrimidin-5-yl)-amide	1,5
1089	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	448
1009	carboxylic acid (3-thiazol-2-yl-phenyl)-amide	110
, <u>.</u>	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1090	carboxylic acid [3-(3-methyl-5-oxo-4,5-dihydro-pyrazol-	461
	1-yl)-phenyl]-amide	
1091	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	482
1051	carboxylic acid (3-benzooxazol-2-yl-phenyl)-amide	
1092	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	408
1072	carboxylic acid (3-carbamoyl-phenyl)-amide	
1093	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	408
1093	carboxylic acid (3-dimethylamino-phenyl)-amide	

· · · · · · · · · · · · · · · · · · ·	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1094	carboxylic acid [3-(2-hydroxy-ethanesulfonyl)-phenyl]-	473
	amide	
	4-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	
1095	4-carbonyl]-amino}-piperidine-1-carboxylic acid tert-	472
	butyl ester	
	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1096	carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-	429
	amide .	
1007	(4-Benzyl-piperazin-1-yl)-[1-(3-fluoro-phenyl)-5-	432
1097	trifluoromethyl-1H-pyrazol-4-yl]-methanone	432
1000	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	350
1098	carboxylic acid pyridin-4-ylamide	
1000	Biphenyl-3-carboxylic acid (2-methyl-5-phenyl-2H-	353
1099	pyrazol-3-yl)-amide	333
1100	Biphenyl-4-carboxylic acid (2-methyl-5-phenyl-2H-	353
1100	pyrazol-3-yl)-amide	333
1101	4'-Chloro-biphenyl-3-carboxylic acid (2-methyl-5-phenyl-	387
1101	2H-pyrazol-3-yl)-amide	30,
	3-{[1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1102	carbonyl]-amino}-piperidine-1-carboxylic acid tert-butyl	456
	ester	
	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1103	carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-	447
	amide	
1104	(4-Benzyl-piperazin-1-yl)-[1-(3,4-difluoro-phenyl)-5-	450
1104	trifluoromethyl-1H-pyrazol-4-yl]-methanone	
1105	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	368
1105	carboxylic acid pyridin-4-ylamide	
	3-{[1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-	
1106	pyrazole-4-carbonyl]-amino}-piperidine-1-carboxylic acid	474
	tert-butyl ester	

1107	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	514
	carboxylic acid [3-(morpholine-4-sulfonyl)-phenyl]-amide	717
	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1108	pyrazole-4-carboxylic acid (2-methyl-5-phenyl-2H-	495
	pyrazol-3-yl)-amide	
1100	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	416
1109	pyrazole-4-carboxylic acid pyridin-4-ylamide	710
	3-{[1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-	
1110	pyrazole-4-carbonyl]-amino}-piperidine-1-carboxylic acid	522
	tert-butyl ester	ļ
	Methanesulfonic acid 1-[1-(4-chloro-phenyl)-5-	
1111	trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidin-4-yl	451
	ester	
1112	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
1112	carboxylic acid (3-methylsulfamoyl-phenyl)-amide	150
1113	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	442
1113	carboxylic acid (3-pyridin-2-yl-phenyl)-amide	
1114	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	442
1114	carboxylic acid (3-pyridin-3-yl-phenyl)-amide	
1115	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	442
1113	carboxylic acid (3-pyridin-4-yl-phenyl)-amide	
1116	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	428
1110	carboxylic acid (3-sulfamoyl-phenyl)-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1117	carboxylic acid (3-trifluoromethanesulfonyl-phenyl)-	497
	amide	
1118	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
1110	carboxylic acid (3-methanesulfonylamino-phenyl)-amide	
1119	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	433
. 1117	carboxylic acid [3-(2H-tetrazol-5-yl)-phenyl]-amide	
	[(3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	
1120	4-carbonyl]-amino}-phenyl)-imino-methyl]-carbamic acid	
	tert-butyl ester	

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1121	carboxylic acid (3-carbamimidoyl-phenyl)-amide	
1122	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	380
	carboxylic acid (3-amino-phenyl)-amide	380
1100	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1123	carboxylic acid (3-ureido-phenyl)-amide	
1107	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	444
1127	carboxylic acid (4-sulfamoyl-phenyl)-amide	
1120	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	422
1130	carboxylic acid (3-acetylamino-phenyl)-amide	722
1101	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	484
1131	carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide	404
1120	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	449
1132	(4-pyridin-2-ylmethyl-piperazin-1-yl)-methanone	
1100	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	449
1133	(4-pyridin-3-ylmethyl-piperazin-1-yl)-methanone	
1134	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	449
1154	(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone	
	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-	
1135	[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-	469
	methanone	
1136	2-Phenyl-2H-pyrazole-3-carboxylic acid pyridin-4-	264
1130	ylamide	
1137	(4-Benzyl-piperazin-1-yl)-(2-phenyl-2H-pyrazol-3-yl)-	346
113/	methanone	
1138	2-Phenyl-2H-pyrazole-3-carboxylic acid (3-	341
1138	methanesulfonyl-phenyl)-amide	J 11
1139	2-Phenyl-2H-pyrazole-3-carboxylic acid (1H-	303
1139	benzoimidazol-2-yl)-amide	
1140	2-Phenyl-2H-pyrazole-3-carboxylic acid 3-	345
1140	trifluoromethyl-benzylamide	
1141	2-Phenyl-2H-pyrazole-3-carboxylic acid (2-methyl-5-	343
1141	phenyl-2H-pyrazol-3-yl)-amide	

1142	2-Phenyl-2H-pyrazole-3-carboxylic acid (3-sulfamoyl-	342
	phenyl)-amide	
1143	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-	360
1145	piperidin-4-yl)-amide	
1144	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-	346
1144	pyrrolidin-3-yl)-amide	540
11.45	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-	346
1145	pyrrolidin-3-yl)-amide	340
1146	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1146	carboxylic acid (3-methylsulfanyl-phenyl)-amide	41/1
4 1 457	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	427
1147	carboxylic acid (3-methanesulfinyl-phenyl)-amide	421
4440	3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-	445
1148	4-carbonyl]-amino}-benzenesulfonic acid	443
<u></u>	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1151	carboxylic acid {3-[(methanesulfonylimino-phenoxy-	577
	methyl)-amino]-phenyl}-amide	
· · ·	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1152	carboxylic acid {3-[(amino-methanesulfonylimino-	500
	methyl)-amino]-phenyl}-amide	-
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1153	carboxylic acid {3-[(methanesulfonylimino-methylamino-	514
	methyl)-amino]-phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1154	carboxylic acid {3-[(cyclopropylamino-	540
	methanesulfonylimino-methyl)-amino]-phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1155	carboxylic acid {3-[(dimethylamino-	528
	methanesulfonylimino-methyl)-amino]-phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1156	carboxylic acid (3-{[(isopropyl-methyl-amino)-	556
	methanesulfonylimino-methyl]-amino}-phenyl)-amide	

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1157	carboxylic acid [3-(2,4-dimethoxy-benzylsulfamoyl)-	594
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1158	carboxylic acid [3-(2-piperidin-1-yl-ethylsulfamoyl)-	555
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1159	carboxylic acid [3-(3-diethylamino-propylsulfamoyl)-	557
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1160	carboxylic acid [3-(2,3-dimethoxy-benzylsulfamoyl)-	594
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1161	carboxylic acid {3-[3-(2-oxo-pyrrolidin-1-yl)-	569
	propylsulfamoyl]-phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1162	carboxylic acid {3-[2-(ethyl-m-tolyl-amino)-	605
	ethylsulfamoyl]-phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1163	carboxylic acid [3-(3-hydroxy-pyrrolidine-1-sulfonyl)-	514
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	500
1164	carboxylic acid (3-butylsulfamoyl-phenyl)-amide	300
	[3-(3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-	-
1165	pyrazole-4-carbonyl]-amino}-benzenesulfonylamino)-	601
	propyl]-carbamic acid tert-butyl ester	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1166	carboxylic acid [3-(3-hydroxy-pyrrolidine-1-sulfonyl)-	514
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1167	carboxylic acid [3-(2-hydroxy-propylsulfamoyl)-phenyl]-	502
	amide	

	(4-Benzyl-piperazin-1-yl)-[1-(4-chloro-phenyl)-5-	440
1168	trifluoromethyl-1H-pyrazol-4-yl]-methanone	448
	(4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(4-chloro-	463
1169	phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	403
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	···
1170	carboxylic acid {3-[(1-ethyl-pyrrolidin-2-ylmethyl)-	555
	sulfamoyl]-phenyl}-amide	
······································	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1171	carboxylic acid [3-(2-diethylamino-ethylsulfamoyl)-	543
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1172	carboxylic acid {3-[2-(4-amino-phenyl)-ethylsulfamoyl]-	. 563
	phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1173	carboxylic acid [3-(2-pyrrolidin-1-yl-ethylsulfamoyl)-	541
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1174	carboxylic acid {3-[(pyridin-3-ylmethyl)-sulfamoyl]-	535
	phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1175	carboxylic acid [3-(2-dimethylamino-ethylsulfamoyl)-	515
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1176	carboxylic acid [3-(thiomorpholine-4-sulfonyl)-phenyl]-	530
	amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1177	carboxylic acid [3-(4-methyl-[1,4]diazepane-1-sulfonyl)-	541
	phenyl]-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1178	carboxylic acid [3-(4-methyl-piperazine-1-sulfonyl)-	527
	phenyl]-amide	

	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1179	carboxylic acid {3-[2-(3-chloro-phenyl)-ethylsulfamoyl]-	582
	phenyl}-amide	
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1180	carboxylic acid {3-[methyl-(2-pyridin-2-yl-ethyl)-	563
	sulfamoyl]-phenyl}-amide	
1101	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	472
1181	carboxylic acid (3-ethylsulfamoyl-phenyl)-amide	412
	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1182	carboxylic acid {3-[(2-hydroxy-ethyl)-methyl-sulfamoyl]-	502
	phenyl}-amide	
1183	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	500
1103	carboxylic acid (3-diethylsulfamoyl-phenyl)-amide	300
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1184	carboxylic acid (6-methanesulfonyl-benzothiazol-2-yl)-	500
•	amide	
1105	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
1185	carboxylic acid (2-methyl-3-sulfamoyl-phenyl)-amide	436
1106	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	458
1186	carboxylic acid (2-sulfamoylmethyl-phenyl)-amide	430
1187	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	478
110/	carboxylic acid (2-chloro-5-sulfamoyl-phenyl)-amide	7/0
····	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-	
1188	carboxylic acid (4-methyl-5-sulfamoyl-thiazol-2-yl)-	465

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to included within the spirit and purview of this application and are considered within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

5

WHAT IS CLAIMED IS:

A compound having the formula: 1. 1 2 or a pharmaceutically acceptable salt thereof, wherein 3 R¹ and R³ are each members independently selected from hydrogen, (C₁-4 C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, 5 amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl; 6 R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, 7 aryl, heteroaryl, aryl(C_1 - C_4)alkyl, and heteroaryl(C_1 - C_4)alkyl; 8 Y is a member selected from: 9 $\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array}$ 10 wherein 11 X is a member selected from O, S and NR8 12 13 wherein R⁸ is a member selected from the group of hydrogen, cyano, nitro, 14 alkyl, acyl, aryl and SO₂R⁹ 15 wherein 16 R⁹ is a member selected from alkyl, aryl, heteroaryl and 17 heterocycloalkyl; 18 R⁴ and R⁵ are each members independently selected from 19 hydrogen, (C1-C10)alkyl, (C3-C7)cycloalkyl, (C1-20 C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, 21 heteroaryl(C_1 - C_4)alkyl and (C_3 - C_8)heterocycloalkyl with 22 the proviso that if \mathbb{R}^4 is hydrogen, \mathbb{R}^5 is not hydrogen; and 23 R⁴ and R⁵ taken together with the nitrogen atom to which 24 they are attached optionally form a 4- to 8-membered 25 heterocycloalkyl ring; 26 R⁶ is a member selected from hydrogen, (C₁-C₆)alkyl, aryl, 27 heteroaryl, aryl(C_1 - C_4)alkyl, heteroaryl(C_1 - C_4)alkyl and 28 (C₁-C₆)heteroalkyl; and 29

R⁷ is a member selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-30 C7) alkenyl, (C1-C6) heteroalkyl, aryl, heteroaryl, aryl(C1-31 C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-32 C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and 33 and R⁶ and R⁷ together with the atoms to which they are 34 attached optionally form a 4- to 8-membered 35 heterocycloalkyl ring. 36 The compound of claim 1 having the formula: 2. 1

R¹ N

2

1 3. The compound of claim 2 wherein Y has a formula which is a member selected from:

3
$$\mathbb{R}^{5}$$
; and \mathbb{R}^{6}

- 1 4. The compound of claim 3 wherein
- 2 R¹ and R³ are each members independently selected from hydrogen, (C₁-
- 3 C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl and (C₁-
- 4 C₅)heteroalkyl; and
- · 5 X is O.
- The compound of claim 4 wherein R² is a member selected from aryl and heteroaryl.
- 1 6. The compound of claim 5 wherein R³ is hydrogen.
- 7. The compound according to claim 6 wherein R¹ is a member selected from hydrogen, (C₁-C₄)alkyl, and (C₁-C₄)haloalkyl.
- 1 8. The compound according to claim 3 wherein R⁴ is a member 2 selected from heteroaryl and heterocycloalkyl; and
- R⁴ and R⁵, together with the nitrogen to which they are bonded are
- 4 optionally joined to form a 4- to 8-membered heterocycloalkyl ring system.

1 9. The compound according to claim 8, wherein R⁴ and R⁵ taken 2 together with the nitrogen to which they are attached form a member selected from:

$$N-R^{12}$$
; and $N-R^{13}$; and $N-R^{13}$.

4

3

10. A compound having the formula:

2

,1

3 4

9

11

or a pharmaceutically acceptable salt thereof, wherein

5 R¹ and R³ are each members independently selected from hydrogen, (C₁-C₄)alkyl,

6 (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo,

7 cyano, nitro, hydroxy, aryl and heteroaryl;

8 R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl,

heteroaryl, aryl(C_1 - C_4)alkyl, and heteroaryl(C_1 - C_4)alkyl;

10 Y is a member selected from:

12 wherein

13 X is a member selected from O, S and NR⁸

14 wherein

15 R⁸ is a member selected from hydrogen, cyano, nitro, alkyl, acyl,

16 aryl and SO₂R⁹

17 wherein

18 R⁹ is a member selected from alkyl, aryl, heteroaryl and

19 heterocycloalkyl;

20 R⁴ has a formula which is a member selected from:

$$\{ \begin{array}{c} A \\ M \end{array} \} = \{ \begin{array}{c} A \\$$

21 22

23 wherein

24	n is an integer from 0 to 4;
25	k is an integer from 1 to 3;
26	R ^{2a} and R ^{2b} are members independently selected from hydrogen
27	and (C1-C4)alkyl, and R2a and R2b taken together with the
28	carbon atom to which they are attached optionally form a 3-
29	to 8-membered carbocyclic or heterocycloalkyl ring;
30	M is a member selected from NR ¹⁰ , O and S
31	wherein
32	R ¹⁰ is a member selected from hydrogen, (C ₁ -C ₆) alkyl, (C ₁ -
33	C_8) heteroalkyl aryl, heteroaryl and (C_3-C_8)
34	cycloalkyl;
35	A, B, D, E and G are independently members selected from N, N-
36	oxide and CR ¹¹ with the proviso that at most three of A, B,
37	D, E and G is N; and at most one of A, B, D, E and G is N-
38	oxide
39	wherein
40	R ¹¹ is a member selected from hydrogen, halo, amino, hydroxy,
41	cyano, nitro, (C1-C4)alkyl, (C3-C7)cycloalkyl, (C1-
42	C ₇)heteroalkyl, aryl, heteroaryl, (C ₃ -C ₈)heterocycloalkyl,
43	alkoxy, acyl, $-C(NR^{12})R^{13}$, $-SO_2R^{15}$, $-SO_2NR^{13}R^{14}$,
44	$-NR^{12}SOR^{15}$, $-NR^{12}SO_2NR^{13}R^{14}$, $-NR^{12}C(N-CN)NR^{13}R^{14}$,
45	$-NR^{12}C(N-SO_2R^{15})NR^{13}R^{14}$, $-NR^{12}C(N-COR^{15})NR^{13}R^{14}$,
46	$-CONR^{13}R^{14}$, $-NR^{12}(C=CH-NO_2)NR^{13}R^{14}$,
47	-NR ¹² CONR ¹³ R ¹⁴ , -NR ¹² CO-OR ¹⁵ , -OCONR ¹³ R ¹⁴ and R ¹¹
48	and R ^{2a} taken together with the carbon atoms to which they
49	are attached optionally form a 4- to 8-membered
50	heterocycloalkyl group with the proviso that A is CR ¹¹
51	wherein
52	R ^{11a} is a member selected from (C ₁ -C ₆)alkyl, (C ₃ -
53	C ₇)cycloalkyl, (C ₃ -C ₈)heterocycloalkyl, aryl and
54	heteroaryl;
55	R ¹² , R ¹³ and R ¹⁴ are members independently selected from
56	hydrogen, (C ₁ -C ₈)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -
57	C ₈)heteroalkyl, aryl, heteroaryl, (C ₃ -

58	C_8) neterocycloalkyl, aryl(C_1 - C_4) alkyl,	
59	heteroaryl(C_1 - C_4)alkyl, amino(C_1 - C_4)alkyl and	
60	when R^{13} and R^{14} are attached to the same nitrog	en
61	atom, they are optionally combined to form a 5-,	6-
62	or 7-membered ring;	
63	R ¹⁵ is a member selected from (C ₁ -C ₈)alkyl, (C ₃ -	
64	C ₈)cycloalkyl, (C ₁ -C ₈)heteroalkyl, aryl, heteroar	yl
65	and (C ₃ -C ₈)heterocycloalkyl;	
66	R ⁵ is a member selected from hydrogen and (C ₁ -C ₄)alkyl; and R ⁵ and R	\ ¹¹
67	taken together with the atoms to which that are attached options	ılly
68	form a 4- to 8-membered heterocycloalkyl ring with the proviso)
69	that A is CR ¹¹	
70	R ⁶ is a member selected from hydrogen, (C ₁ -C ₆)alkyl, aryl, heteroaryl,	
71	$aryl(C_1-C_4)alkyl$, heteroaryl $(C_1-C_4)alkyl$ and (C_1-C_6) heteroalky	l;
72	and	
73	R ⁷ is a member selected from (C ₁ -C ₇)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -	
74	C_7) alkenyl, (C_1-C_6) heteroalkyl, aryl, heteroaryl, aryl (C_1-C_4) alk	yl,
75	heteroaryl(C1-C4)alkyl, amino, alkoxy, (C3-C8)heterocycloalky	l
76	and amino(C1-C5)alkyl, and R6 and R7 taken together with the	
77	atoms to which they are attached optionally form a 4- to 8-	
78	membered heterocycloalkyl ring.	
1	11. The compound of claim 10 wherein R^1 and R^3 are each member	rs
2	independently selected from hydrogen, (C ₁ -C ₄)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -C ₄)haloa	
3	and (C ₁ -C ₅)heteroalkyl; and X is O.	
1	12. The compound of claim 11 wherein R ² is a member selected from	om
2	aryl and heteroaryl.	
1	13. The compound of claim 11 wherein one only of A, B, C, D or I	E is
2	an N or N-oxide.	
1	14. A compound having the formula:	
2		

$$R^1$$
 N
 N
 R^3

3

4 or a pharmaceutically acceptable salt thereof, wherein

5 R¹ and R³ are each members independently selected from hydrogen, (C₁-C₄)alkyl,

6 (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo,

7 cyano, nitro, hydroxy, aryl and heteroaryl;

8 R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl,

9 heteroaryl, $aryl(C_1-C_4)alkyl$, and heteroaryl $(C_1-C_4)alkyl$;

Y is a member selected from:

11 12

10

R⁴ has a formula which is a member selected from:

$$(CR^{2a}R^{2b})$$
 T^{1}
 T^{3}

13 14

wherein

W is a member selected from S, SO and SO₂;

n is an integer from 0 to 4;

17 R^{2a} and R^{2b} are members independently selected from hydrogen and (C₁18 C₄)alkyl, and R^{2a} and R^{2b} taken together with the carbon atom to
19 which they are attached optionally form a 3- to 8-membered

20 carbocyclic or heterocycloalkyl ring;

21 R¹⁵ is a member selected from (C₁-C₄)alkyl, (C₁-C₆)alkenyl, (C₃-

22 C₇)cycloalkyl, aryl, heteroaryl, (C₁-C₈)heteroalkyl, NR¹⁶R¹⁷

23 wherein

24 R¹⁶ and R¹⁷ are members independently selected from hydrogen,

25 (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, (C₃-

26 C₈)heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl,

27 heteroaryl(C₁-C₄)alkyl, amino(C₁-C₄)alkyl, with the proviso

28 that when R¹⁵ is amino W is SO₂;

29	T^1 , T^2 , T^3 and T^4 are each members independently selected from hydrogen,
30	halo, amino, cyano, nitro, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C1-
31	C ₄)haloalkyl, alkoxy, fluoro(C ₁ -C ₄)alkoxy, (C ₁ -C ₇)cycloalkyl, (C ₁ -
32	C_7)heteroalkyl, aryl and heteroaryl, and T^1 and T^2 taken together
33	with the carbon atoms to which they are attached optionally form a
34	4- to 8-membered carbocyclic or heterocycloalkyl ring; T ² and T ³
35	taken together with the carbon atoms to which they are attached
36	optionally form a 4- to 8-membered carbocyclic or
37	heterocycloalkyl ring; T ³ and R ¹⁵ taken together with the atoms to
3 8	which they are attached optionally form a 4- to 8-membered
39	carbocyclic or heterocycloalkyl ring; and T ⁴ and R ¹⁵ taken together
40	with the atoms to which they are attached optionally form a 4-to 8-
41	membered carbocyclic or heterocycloalkyl ring; and
42	R ⁵ is a member selected from hydrogen and (C ₁ -C ₄)alkyl; R ⁵ and T ¹ taken
43	together with the atoms to which they are attached optionally form
44	a 4- to 8-membered heterocycloalkyl ring, and R ⁵ and T ⁴ taken
45	together with the atoms to which they are attached optionally form
46	a 4- to 8-membered heterocycloalkyl ring.
1	15. The compound of claim 14 wherein R ¹ and R ³ are each members
2	independently selected from hydrogen, (C ₁ -C ₄)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -C ₄)haloalkyl
3	and (C ₁ -C ₅)heteroalkyl; and X is O.
1	16. The compound of claim 14 wherein R ² is a member selected from
2	aryl and heteroaryl.
1	17. The compound of claim 15 wherein W is SO ₂ ; and R ¹¹ is selected
2	from substituted or unsubstituted (C ₁ -C ₄)alkyl and NR ¹⁶ R ¹⁷ ; and n is 0.
1	18. A method of decreasing ion flow through voltage-dependent
2	sodium channels in a cell, said method comprising contacting said cell with a sodium
3	channel-inhibiting amount of a compound comprising a pyrazolyl moiety.
1	19. The method according to claim 18, wherein said cell is in a human.

1 20. A method of decreasing ion flow through voltage-dependent 2 sodium channels in a cell, said method comprising contacting said cell with a sodium 3 channel-inhibiting amount of a compound of the formula: 4 5 or a pharmaceutically acceptable salt thereof, wherein R^1 and R^3 are each members independently selected from hydrogen, (C₁-6 C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, 7 8 amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl; R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, .9 aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl; 10 11 Y is a member selected from: 1 12 13 wherein X is a member selected from O, S and NR⁸ 14 15 wherein 16 R⁸ is a member selected from the group of hydrogen, cyano, nitro. alkyl, acyl, aryl and SO₂R⁹ 17 18 wherein R⁹ is a member selected from alkyl, aryl, heteroaryl and 19 heterocycloalkyl; 20 R⁴ and R⁵ are each members independently selected from 21 22 hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-23 C_8)heteroalkyl, aryl, heteroaryl, aryl(C_1 - C_4)alkyl, 24 heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl with the proviso that if R⁴ is hydrogen, R⁵ is not hydrogen; and 25 R⁴ and R⁵ taken together with the nitrogen atom to which 26 27 they are attached optionally form a 4- to 8-membered 28 heterocycloalkyl ring;

29	R ⁶ is a member selected from hydrogen, (C ₁ -C ₆)alkyl, aryl,		
30	heteroaryl, aryl(C_1 - C_4)alkyl, heteroaryl(C_1 - C_4)alkyl and		
31	(C ₁ -C ₆)heteroalkyl; and		
32	R ⁷ is a member selected from (C ₁ -C ₇)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₃ -C ₇)cycloalkyl, (C ₃ -C ₇)cycloalkyl,		
33	C_7)alkenyl, (C_1 - C_6)heteroalkyl, aryl, heteroaryl, aryl(C_1 -		
34	C ₄)alkyl, heteroaryl(C ₁ -C ₄)alkyl, amino, alkoxy, (C ₃ -		
35	C ₈)heterocycloalkyl and amino(C ₁ -C ₅)alkyl, and		
36	and R ⁶ and R ⁷ together with the atoms to which they are		
37	attached optionally form a 4- to 8-membered		
38	heterocycloalkyl ring.		
1	21. A method of treating a central or peripheral nervous system		
2	disorder or condition through inhibition of a voltage-dependent sodium channel, said		
3	method comprising administering to a subject in need of such treatment, an effective		
4	amount of a compound comprising a pyrazolyl moiety.		
•	amount of a compound comprising a pyrazory morety.		
1	22. The method according to claim 21, said compound having the		
2	formula:		
	R^1 , R^2		
3	R_{N}^{1} $Y_{N}^{P^{2}}$ X_{N}^{N}		
4	or a pharmaceutically acceptable salt thereof, wherein		
5	R ¹ and R ³ are each members independently selected from hydrogen, (C ₁ -		
6	•		
7	C ₄)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -C ₄)haloalkyl, (C ₁ -C ₆)heteroalkyl,		
8	amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;		
9	R^2 is a member selected from hydrogen, (C_1-C_4) alkyl, (C_1-C_7) cycloalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, and heteroaryl (C_1-C_4) alkyl;		
10	Y is a member selected from: Y is a member selected from:		
	N^{R^4} ; N^{R^4} ; N^{R^4} ; N^{R^4} ; and N^{R^7} ; and N^{R^7}		
11			
12	wherein		
13	X is a member selected from O, S and NR ⁸		
14	wherein		

15		R° is a member selected from the group of hydrogen, cyano, nitro,
16		alkyl, acyl, aryl and SO_2R^9
17		wherein
18	•	R ⁹ is a member selected from alkyl, aryl, heteroaryl and
19	•	heterocycloalkyl;
20		R ⁴ and R ⁵ are each members independently selected from
21		hydrogen, (C ₁ -C ₁₀)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -
22		C ₈)heteroalkyl, aryl, heteroaryl, aryl(C ₁ -C ₄)alkyl,
23		heteroaryl(C ₁ -C ₄)alkyl and (C ₃ -C ₈)heterocycloalkyl with
24		the proviso that if R ⁴ is hydrogen, R ⁵ is not hydrogen; and
25		R ⁴ and R ⁵ taken together with the nitrogen atom to which
26		they are attached optionally form a 4- to 8-membered
27		heterocycloalkyl ring;
28		R ⁶ is a member selected from hydrogen, (C ₁ -C ₆)alkyl, aryl,
29		heteroaryl, aryl(C ₁ -C ₄)alkyl, heteroaryl(C ₁ -C ₄)alkyl and
30		(C_1-C_6) heteroalkyl; and
31		R ⁷ is a member selected from (C ₁ -C ₇)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -
32		C ₇)alkenyl, (C ₁ -C ₆)heteroalkyl, aryl, heteroaryl, aryl(C ₁ -
33		C ₄)alkyl, heteroaryl(C ₁ -C ₄)alkyl, amino, alkoxy, (C ₃ -
34		C ₈)heterocycloalkyl and amino(C ₁ -C ₅)alkyl, and
35		and R ⁶ and R ⁷ together with the atoms to which they are
36		attached optionally form a 4- to 8-membered
37		heterocycloalkyl ring.
1	23.	The method according to claim 20, wherein said disorder is pain
2		matory pain, neuropathic pain and combinations thereof.
-	serected from minum	natory pain, neuropaune pain and combinations mereor.
1	24.	A composition comprising a pharmaceutically acceptable excipient
2	and a compound havi	ing the formula:
		R^{1} R^{2}
2		R ¹ R ² Y W N ₃
3 4	or a nharmace	cutically acceptable salt thereof, wherein
	PAAGEALIUU	wareant acceptacte care aterest, willight

5	R ¹ and R ³ are each members independently selected from hydrogen, (C ₁ -
6	C_4)alkyl, (C_3 - C_7)cycloalkyl, (C_1 - C_4)haloalkyl, (C_1 - C_6)heteroalkyl,
7	amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;
8	R ² is a member selected from hydrogen, (C ₁ -C ₄)alkyl, (C ₁ -C ₇)cycloalkyl,
9	aryl, heteroaryl, aryl(C_1 - C_4)alkyl, and heteroaryl(C_1 - C_4)alkyl;
10	Y is a member selected from:
11	\mathbb{R}^{6} ; \mathbb{R}^{6} ; \mathbb{R}^{7} ; and \mathbb{R}^{7}
11 12	wherein
13	X is a member selected from O, S and NR ⁸
14	wherein
15	R ⁸ is a member selected from the group of hydrogen, cyano, nitro,
16	alkyl, acyl, aryl and SO ₂ R ⁹
17	wherein
18	R ⁹ is a member selected from alkyl, aryl, heteroaryl and
19	heterocycloalkyl;
20	R ⁴ and R ⁵ are each members independently selected from
21	hydrogen, (C ₁ -C ₁₀)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -
22	C_8)heteroalkyl, aryl, heteroaryl, aryl(C_1 - C_4)alkyl,
23	heteroaryl(C ₁ -C ₄)alkyl and (C ₃ -C ₈)heterocycloalkyl with
24	the proviso that if R ⁴ is hydrogen, R ⁵ is not hydrogen; and
25	R ⁴ and R ⁵ taken together with the nitrogen atom to which
26	they are attached optionally form a 4- to 8-membered
27	heterocycloalkyl ring;
28	R ⁶ is a member selected from hydrogen, (C ₁ -C ₆)alkyl, aryl,
29	heteroaryl, aryl(C1-C4)alkyl, heteroaryl(C1-C4)alkyl and
30	(C_1-C_6) heteroalkyl; and
31	R ⁷ is a member selected from (C ₁ -C ₇)alkyl, (C ₃ -C ₇)cycloalkyl, (C ₁ -
32	C ₇)alkenyl, (C ₁ -C ₆)heteroalkyl, aryl, heteroaryl, aryl(C ₁ -
33	C ₄)alkyl, heteroaryl(C ₁ -C ₄)alkyl, amino, alkoxy, (C ₃ -
34	C ₈)heterocycloalkyl and amino(C ₁ -C ₅)alkyl, and

	WO 03/037274	PCT/US02/35172
35		and R ⁶ and R ⁷ together with the atoms to which they are
36		attached optionally form a 4- to 8-membered
37		heterocycloalkyl ring.

FIG. 1A

compound #	Structure	MZ
790	F F CI	405
791	H H F F CI	494
831	O H H F F F CI	482
1043	N O F F F CI	516
1047	H ₂ N N O F F F CI	439
1048	N O F F F CI	467
1124	HN OFF ON N H N CI	524
1125	NH OFF N H N CI	461

FIG. 1B

1126	N N O F F F N N CI	447
1128	HN N N N N N N N N N N N N N N N N N N	475
1129	HN NH N HN HN	487
1149	OS-NH H	459
1150	O N H	487

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 8 May 2003 (08.05.2003)

PCT

(10) International Publication Number WO 03/037274 A3

- (51) International Patent Classification7: C07D 231/10, 401/12, A61K 31/415
- (21) International Application Number: PCT/US02/35172
- (22) International Filing Date:

1 November 2002 (01.11.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/335,958

1 November 2001 (01.11.2001) US

- (71) Applicant (for all designated States except US): ICA-GEN, INC. [US/US]; Suite 460, 4222 Emperor Boulevard, Durham, NC 27703 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ATKINSON, Robert, Nelson [US/US]; 11908 Radner Way, Raleigh, NC 27613 (US). GROSS, Michael, Francis [US/US]; 6200 Chesden Drive, Durham, NC 27713 (US).
- (74) Agents: MANN, Jeffry, S. et al.; Townsend Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CΛ 94111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- (88) Date of publication of the international search report: 30 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE-AMIDES AND-SULFONAMIDES

(57) Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazole-amides and -sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35172

Decumentation searched other than minimum documentation to the extent that such documents are included in the fields searched	A CLASSICATION OF CURECT MATTER			
According to the fremational Parent (Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched classification system followed by classification symbols) U.S.: \$48/364.1, 374.1; \$14/406 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. 1-17 A US 6,300.363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 Leading the present state of the an which is not considered to be of practical relevance. The column of the continuation cannot be considered to more and the policiation are invested to the consideration on parm published on or after the international filing date or gracing the enterous of particular relevance; the chained investion cannot be considered to involve an inventive tape when the document is taken alone when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the document is considered to involve an inventive tape when the docum	A. CLASSIFICATION OF SUBJECT MATTER			
B. FIELDS SEARCHED		•		
Minimum documentation searched (classification system followed by classification symbols) U.S.: \$548/364.1, 374.1; \$14/406 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched leteronic data base consulted during the international search (name of data base and, where practicable, search terms used) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 2- Special cargories of cited documents **A* document defining the general state of the an which is not considered to be of particular inference of particular inference in the international fling date of principle or principle and published date the international fling date or principle or beety underlying the invertion or principle and or principle an		siana) alassificacion and IDC		
Minimum documentation searched (classification system followed by classification symbols) U.S.: 548/364.1, 374.1; 514/406 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620.865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. I-17 US 6,300.363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 US 6,300.363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 US 6,300.363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 Liter document published after the international filing date of principle or dreay underlying the international filing date of principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international filing date or principle or dreay underlying the international document or involve an investion expendent or principle or dreay underlying the internation c		tional classification and IPC	· · · · · · · · · · · · · · · · · · ·	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CS ONLINE, EAST Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. LUS 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. 1-24 Iter document defining the general state of the an which is not considered to be of particular relevance. **Committee and the application or patent published on or after the international filing date or priority claims; or which is cited to expect the publication date of a state of the special reason to a specified or a state of the special reason to a specified or a state of the special reason to a specified or a state of the special reason to a specified or a state of the special reason to a specified or the special reason to a specified to involve an inventive step when the document is sentiled to the special reason to a specified to involve an inventive step when the document is sentiled to the special reason to a specified to involve an inventive step when the document is continued with one or more other special reason to a specified to involve an intentive step when the document is continued with one or more other special reason to a specified to involve an intentive step when th	B. FIELDS SEARCHED			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. It 17 US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. It are document defining the general saar of the an which is not considered to be of particular relevance. The calling the general saar of the an which is not considered to the continuant of particular relevance. The calling the general saar of the an which is inde to specified out the specification of patent published on or after the imenational filing date. The document which may those doubts on priority claim(s) or which is cited to especified? The document which may those doubts on priority claim(s) or which is cited to especified. The document which may those doubts on priority claim(s) or which is cited to especified. The document which may those doubts on priority claim(s) or which is cited to especified. The document which may those doubts on priority claim(s) or which is cited to especified. The document which may those doubts on priority claim(s) or which is cited to especified. The document which may those doubts on priority claim(s) or which is cited to especified in which is the other document is document of particular relevance. The claimed of the document is experied. The document which may those doubts on priority claim(s) or which is cited to especified to involve an inversior sarp when the document is experied. The document which may those doubts on priority claim(s) or which is cited to especified to involve an inversior sarp when the document is experied. The document which may those doubts on priori	Minimum documentation searched (classification system followed b	oy classification symbols)		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A	· · · · · · · · · · · · · · · · · · ·	,,		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A		·		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A	Documentation searched other than minimum documentation to the	extent that such documents are included in	the fields searched	
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. I-17 A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document offining the general state of the an which is not considered to be of particular trelevance. "E" earlier application or patent published on or after the international filing date crashibits the publication date of another citation or other special ration (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date the international filing date to causile the three published prior to the international filing date to the international filing date to causile the document is obtained invention cannot be considered to involve an inventive sup when the document is combined with one or more other special ration (as "Y" specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search [6 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P. O. Box 1450 Attendation. Yellow and the priority claims 22313-1450				
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. I-17 A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document offining the general state of the an which is not considered to be of particular trelevance. "E" earlier application or patent published on or after the international filing date crashibits the publication date of another citation or other special ration (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date the international filing date to causile the three published prior to the international filing date to the international filing date to causile the document is obtained invention cannot be considered to involve an inventive sup when the document is combined with one or more other special ration (as "Y" specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search [6 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P. O. Box 1450 Attendation. Yellow and the priority claims 22313-1450				
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. I-17 A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document offining the general state of the an which is not considered to be of particular trelevance. "E" earlier application or patent published on or after the international filing date crashibits the publication date of another citation or other special ration (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date the international filing date to causile the three published prior to the international filing date to the international filing date to causile the document is obtained invention cannot be considered to involve an inventive sup when the document is combined with one or more other special ration (as "Y" specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search [6 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P. O. Box 1450 Attendation. Yellow and the priority claims 22313-1450				
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. I-17 A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document offining the general state of the an which is not considered to be of particular trelevance. "E" earlier application or patent published on or after the international filing date crashibits the publication date of another citation or other special ration (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date the international filing date to causile the three published prior to the international filing date to the international filing date to causile the document is obtained invention cannot be considered to involve an inventive sup when the document is combined with one or more other special ration (as "Y" specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search [6 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P. O. Box 1450 Attendation. Yellow and the priority claims 22313-1450	Electronic data hase consulted during the international search (nam	e of dots bose and jubare prosticable, see-	oh some word)	
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A US 4,620,865 (BECK et al.) 4 Nov 1986 (4.11.1986), column 1-7. I-24 US 6,300,363 (Stevens et al.) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special cargories of cited documents: -*		e oi data base and, where practicable, sear	ch terms used)	
Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. LUS 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. LUS 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document defining the general state of the an which is not considered to be of particular relevance. "E" earlier application or patent published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invertion cause to establish the published on a far other citation or other special reason tas establish the published date of another citation or other special reason tas established to published priority date invertion cause to establish the published date of another citation or other special reason tas established or other special reason tas established priority date claimed "T" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document published prior to the international filing date but later than the priority dat	CAS ONLINE, EASI			
Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. LUS 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. LUS 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document defining the general state of the an which is not considered to be of particular relevance. "E" earlier application or patent published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invertion cause to establish the published on a far other citation or other special reason tas establish the published date of another citation or other special reason tas established to published priority date invertion cause to establish the published date of another citation or other special reason tas established or other special reason tas established priority date claimed "T" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document published prior to the international filing date but later than the priority dat				
Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. LUS 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7. LUS 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5. * Special categories of cited documents: "A" document defining the general state of the an which is not considered to be of particular relevance. "E" earlier application or patent published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invertion cause to establish the published on a far other citation or other special reason tas establish the published date of another citation or other special reason tas established to published priority date invertion cause to establish the published date of another citation or other special reason tas established or other special reason tas established priority date claimed "T" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "P" document referring to an oral disclosure, use, exhibition or other special reason tasses established priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document referring to an oral disclosure, use, exhibition or other special reason tasses established prior to the international filing date but later than the priority date claimed "A" document published prior to the international filing date but later than the priority dat	C DOCUMENTS CONSIDERED TO BE RELEVANT	· · · · · · · · · · · · · · · · · · ·		
Further documents are listed in the continuation of Box C. See patent family annex.				
Further documents are listed in the continuation of Box C. * Special cargories of cited documents: *A* document defining the general state of the an which is not considered to be of particular relevance *C* earlier application or patent published on or after the international filing date or priority date and not include with the application but cited to understand the principle of theory underlying the inversion of considered novel or cannot be considered involve an investible aspecifical or cannot be considered to mode an investible aspecification of the international filing date or priority date and not of considered novel or cannot be considered to involve an investible aspecification of the international filing date or priority date and not of document referring to an oral disclosure, use, exhibition or other special reason (as specificated) **T* document referring to an oral disclosure, use, exhibition or other means **P* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed **Date of the actual completion of the international search fol May 2003 (16.05.2003) **Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 **T* Later document family annex. 1ater document published after the international filing date or priority date and not or decument incurred to considered novel or cannot be considered to revolve an investion cannot be considered to involve an investion cannot be considered to expect the chainted to involve an investion canno			Relevant to claim No.	
Further documents are listed in the continuation of Box C. See patent family annex. The special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance of particular	A US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986)), column 1-7.	1-17	
Further documents are listed in the continuation of Box C. See patent family annex. The special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance of particular				
Further documents are listed in the continuation of Box C. See patent family annex. The special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance of particular	A US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5.	1-24	
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450		,, ., ., ., ., ., ., ., ., ., ., ., ., .		
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450	i			
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450	i			
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450				
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450			<u> </u>	
Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered no involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450	Further documents are listed in the continuation of Rox C	See natent family annex		
date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered not be of particular relevance. "A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier application or patent published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document published prior to the international filing date but later than the priority date claimed. "A" document member of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family. Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (703) 308-1235				
-A" document defining the general state of the art which is not considered to be of particular relevance -E" earlier application or patent published on or after the international filing date -E" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) -O" document referring to an oral disclosure, use, exhibition or other means -P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Artifortized of the considered to involve an invention cannot be considered to involve an invention cannot be considered no involve an inventive step when the document is considered to involve an inventive step when the document is considered to involve an inventive step when the document is considered to involve an inventive step when the document is considered to involve an inventive step when the document is considered to involve an inventive step when the document is considered no involve an inventive step when the document is considered to involve an inventive step when the document is considered no involve an inventive step when the document of particular relevance; the claimed invention cannot be considered no involve an inventive step when the document is considered no involve an inventive step when the document is considered no involve an inventive step when the document is considered no involve an inventive step when the document of particular relevance; the claimed invention cannot be considered no involve an inventive step when the document of particular relevance; the claimed document of particular relevance; the claimed invention cannot be considered no involve an inventive step when the document of particular relevance; the claimed to invo	 Special categories of cited documents: 	· · · · · · · · · · · · · · · · · · ·		
of particular relevance "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "V" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search I6 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Action 15 Acti	*A" document defining the general state of the on which is not considered to be			
The earlier application or parent published on or after the international filing date occusion which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) The document referring to an oral disclosure, use, exhibition or other means The document published prior to the international filing date but later than the priority date claimed The document published prior to the international filing date but later than the priority date claimed The document published prior to the international filing date but later than the priority date claimed The document published prior to the international filing date but later than the priority date claimed The document published prior to the international filing date but later than the priority date claimed The document published prior to the international filing date but later than the priority date claimed The document member of the same patent family The document member of the same patent family The document published prior to the international search The document published prior to the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family The document published prior to the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document is combined with one or more other such document is combined with one or more other such documents. The document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such doc		prompte of theory underlying the inve	14100	
"C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document published prior to the international filing date but later than the priority date claimed "Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Commissioner for Date of the internation of the international filing date but later than the priority date claimed Considered novel or cannot be considered to involve an inventive step when the document staken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed inventive step when the document is taken alone "Y" document of particular relevance: the claimed with one or more other such document is taken alone "Y" document of particular relevance: the claimed with one or more other such document is taken alone "Y" document of particular relevance: the claimed with one or more other such documents, such combination being obvious to a person skilled in the art "A" document published prior to the international filing date but later than the combination of the international filing date but later than the priority date claimed with one or more other such docume	p	"X" document of particular relevance; the	claimed invention cannot be	
-L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) -O" document referring to an oral disclosure, use, exhibition or other means -P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 A decament which may throw doubts on priority claim(s) or which is cited to establish the publication of a document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art -A" document member of the same patent family -A" Date of mailing of the international search report Colam M Shameem Felephone No. (703) 308-1235	"E" earlier application or patent published on or after the international filing date	considered novel or cannot be conside		
establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search In May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Action of the internation of the international search Telephone No. (703) 308-1235		when the document is taken alone		
specified) considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the an document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Considered to involve an inventive step when the document is combination being obvious to a person skilled in the an document member of the same patent family Date of mailing of the international search report Golam M Shameem Telephone No. (703) 308-1235		tv* dominant ofi	atalanad languages	
combined with one or more other such documents, such combination being obvious to a person skilled in the an document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Commissioner No. (703) 308-1235				
"P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 being obvious to a person skilled in the an document member of the same patent family Date of mailing of the international search report 4 Mountain member of the same patent family The priority date claimed document member of the same patent family Antibody and the international search of the international search report of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document member of the same patent family The priority date claimed document family The pri	specially			
P document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Actual Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (703) 308-1235	"O" document referring to an oral disclosure, use, exhibition or other means			
Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Date of mailing of the international search report 26 JUN 2003 Administrational search report Column Shameem Telephone No. (703) 308-1235	·	•		
Date of the actual completion of the international search 16 May 2003 (16.05.2003) Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Date of mailing of the international search report 26 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (703) 308-1235		"&" document member of the same patent	family	
Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Ammorized officer Golam M Shameem Telephone No. (703) 308-1235	priority date claimed			
Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Ammorized officer Golam M Shameem Telephone No. (703) 308-1235	Date of the actual completion of the international search Date of mailing of the international search report			
Name and mailing address of the ISA/US Mail Stop PCT. Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Ammorized officer Golam M Shameem Telephone No. (703) 308-1235				
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Annovized officer Golam M Shameem Telephone No. (703) 308-1235				
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Golam M Shameem Telephone No. (703) 308-1235	Name and mailing address of the ISA/US Antitorized officer/and (a)			
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Golam M Shameem Telephone No. (703) 308-1235	1	Joseph KM 9K-1		
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (703) 308-1235		Golam M Shameem		
Atexandria, Virginia 22313-1450 Telephone No. (703) 308-1235	P.O. Rox 1450			
Facsimile No. (703)305-3230	Alexandria, Virginia 22313-1450 Telephone No. (703) 308-1235			
	Facsimile No. (703)305-3230			
Form PCT/ISA/210 (second sheet) (July 1998)		1		